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1. Introduction 
Pain is ubiquitous and serves an important protective function. However, pain also causes a 
burden both to the patient and to society (Krismer & van Tulder, 2007; Wenig, Schmidt, 
Kohlmann, & Schweikert, 2009). Musculoskeletal disorders, especially back pain (BP), are 
responsible for more days of sick leave than any other illness (DAK-Gesundheit, 2012; 
Techniker-Krankenkasse, 2012). Almost every person experiences BP at least once in their 
life (Schmidt et al., 2007), and the average prevalence of current chronic back pain (CBP) is 
10-27% (Freburger et al., 2009; Picavet & Schouten, 2003; B. H. Smith, Elliott, Hannaford, 
Chambers, & Smith, 2004).  
The most common type of CBP, non-specific CBP (Deyo, Rainville, & Kent, 1992), is the 
focus of this dissertation thesis. Although the word “chronic” implies that this pain cannot be 
healed, the ability to ameliorate this pain through treatment also seems to be low (Keller, 
Hayden, Bombardier, & van Tulder, 2007; Machado, Kamper, Herbert, Maher, & McAuley, 
2009; Stein, Reinecke, & Sorgatz, 2010). Therefore, research is necessary to decrease the 
burden of CBP for both patients and society.  
One important limitation of previous research is related to the methodologies used in these 
studies. Many studies have investigated highly selective clinical samples or very 
heterogeneous samples and used non-validated instruments. This hampers the 
generalization of their results. Therefore, there is not only a need for more research in 
general but also for research with high methodological quality in particular.  
This research must consider that CBP seems to be a complex condition that usually involves 
further symptoms in addition to pain in the back. Furthermore, the group of patients with CBP 
is reportedly heterogeneous (Natvig, Bruusgaard, & Eriksen, 2001; A. Raspe, Matthis, Héon-
Klin, & Raspe, 2003). Therefore, CBP is best described by a bio-psychosocial model 
(Gatchel, Peng, Peters, Fuchs, & Turk, 2007; Kikuchi, 2008). Application of such a model 
has been neglected; this is a second limitation of prior research. Therefore, a comprehensive 
assessment of psychosocial aspects and further co-morbidities is necessary to account for 
the complexity of CBP.  
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Although mechanism-based approaches were introduced long ago (Woolf et al., 1998), they 
have been neglected in research. The lack of specific mechanism-based treatment options 
might explain the current insufficiency of treatment. Thus, potential pathophysiological 
mechanisms should be studied and linked with clinical variables. 
In summary, there is a need for research with high methodological quality that accounts for 
the complexity of CBP and links clinical manifestations with pathophysiological findings. The 
five studies encompassed by this dissertation thesis will contribute to a better understanding 
of CBP and foster the development of new treatment options and diagnostic markers.  
In the first study, we determined the prevalence of non-specific CBP in a representative 
population-based sample in Germany to address the lack of valid recent information on this 
topic. Moreover, we considered the spatial extent of the pain and the bio-psychosocial model 
to verify that the group of CBP patients is heterogeneous. In the second study, we estimated 
the type and the prevalence of mental co-morbidities in the same sample. Previous studies 
may have overestimated the prevalence of mental disorders in CBP due to their use of highly 
selected clinical samples that might be especially burdened by their pain. In the third study, 
we examined the psychophysiological heterogeneity of CBP patients because it has been 
suggested that CBP patients also differ in neurobiological aspects. In the fourth study, we 
considered psychophysiological aspects of physical activity. Physical activity is a part of most 
CBP treatment programs, but the pathophysiological mechanisms underlying the 
effectiveness of physical activity remain largely unclear. In the fifth manuscript, we combined 
the results of the previous four studies and introduced a new study designed based on them 
and the most recent findings in regard to CBP. The study aims to identify mechanism-based 
subgroups of CBP patients and subsequently develop subgroup-specific treatment options. 
In conclusion, the author has aimed to foster CBP research by combining the methodological 
advantages of population-based studies and clinical methods. Thereby, clinical data 
collected with validated instruments will be brought together with psychophysiological 
patterns. This will account for the heterogeneity of CBP patients and stimulate the 
development of new subgroup-specific treatment options.
7 
2.0 Background
2.1 Musculoskeletal pain: definition and classification
According to the definition accepted by the International Association for the Study of Pain 
(IASP), pain is an “unpleasant sensory and emotional experience associated with actual or 
potential tissue damage or described in terms of such damage” (Mersky, 1979). This 
definition highlights the subjective aspects of pain that must be considered in research. 
Musculoskeletal pain is pain of the bones, joints, muscles, or surrounding structures. The 
most common location of musculoskeletal pain is the back, which accounts for 22% to 48% 
of all musculoskeletal pain (Chung & Wong, 2007; Gureje, Von Korff, Simon, & Gater, 1998). 
Low BP, the most common type of BP, is defined as pain localized between the 12th rib and 
the inferior gluteal folds, with or without leg pain (Airaksinen et al., 2006). With regard to the 
pathology associated with BP, only 5% to 10% of BP cases are associated with a 
pathophysiological correlate (e.g., an inflammatory or degenerative disease such as spinal 
stenosis, fracture, disc hernia, ankylosing spondylitis, or rheumatoid arthritis). In most cases 
(>90%), the BP is non-specific (Deyo et al., 1992). This is a diagnosis of exclusion, meaning 
that no cause or structure responsible for the pain can be determined with currently available 
evaluation and/or diagnostic tools (S. S. Weiner & Nordin, 2010).  
BP patients are categorized as acute, sub-acute, or chronic cases according to the duration 
of the pain. Acute BP occurs suddenly and lasts for less than 6 weeks. Pain that persists for 
more than 6 weeks but less than 3 months is classified as sub-acute. Pain with duration of 
more than 3 months is usually classified as chronic (Krismer & van Tulder, 2007). The focus 
of this dissertation thesis is non-specific chronic low BP. For simplicity, this entity will be 
referred to as CBP.  
One important concept in CBP is the spatial extent of the pain, which is usually captured 
using a pain drawing. A pain drawing is a diagram of the body. Patients are usually asked to 
mark all areas in which they experience pain on the pain drawing (Figure 1a). It is possible to 
classify patients in different categories of pain extent based on these pain drawings. The 
commonly used categories are “chronic local pain” (CLP) and “chronic widespread pain” 
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(CWP). CWP is defined as axial pain (cervical, thoracic, lumbar, or sacral spine) with 
contralateral limb pain, whereas CLP is defined as all non-CWP (Wolfe et al., 1990). A 
transparent template can be used to facilitate the classification of CLP and CWP (Figure 1b). 
However, the spatial extent of the pain is a neglected aspect of CBP, and the designations of 
CLP and CWP might not fully describe the heterogeneity of CBP patients. Therefore, 
research that links pain extent with clinical variables and neurobiological correlates is 
necessary. 
Figure 1a. Patients are asked to indicate all areas of 
their body in which they experience pain.  
Figure 1b. The transparent template indicates the 
boundaries of each body region. It is placed over the 
drawings to assist in analysis.  
2.2 Epidemiology of chronic musculoskeletal pain 
Epidemiology is the study of the distribution and patterns of diseases or health-related 
variables and their causes or influences in well-defined populations. Thus, risk factors for 
diseases and targets for preventive approaches can be identified. One important concept in 
epidemiology is prevalence. Prevalence is defined as the proportion of cases in a population 
that satisfy the criteria for a respective disease (or e.g., a behavior or risk factor) at a given 
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time point. Thus, it is possible to estimate how common a risk factor is in the population over 
a certain period of time (Gordis, 2009). In CBP research, the time periods are usually defined 
as “in the moment” (point-prevalence/current prevalence rate), “within the last year” (one-
year prevalence rate), or “once in your life” (lifetime prevalence rate; Hoy et al., 2012).  
Chronic pain of the musculoskeletal system is common. Studies report current prevalence 
rates from 13.5% to 47%, with a mean prevalence of approximately 30% (Cimmino, Ferrone, 
& Cutolo, 2011). Lifetime prevalence for BP varies between 48% and 84% (G. B. J. 
Andersson, 1999; McBeth & Jones, 2007). These values are consistent with those of a 
recent German study that reported a current prevalence of 37.1%, a 1-year prevalence of 
76%, and a lifetime prevalence of 85.5% for BP (Schmidt et al., 2007). However, this study 
did not report prevalence values for CBP. 
With regard to chronic conditions, the average current prevalence rates are 10-27% for CBP 
(Freburger et al., 2009; Picavet & Schouten, 2003; B. H. Smith et al., 2004) and 7-13% for 
CWP (Gran, 2003; Staud, 2009). The wide range of prevalence rates likely reflects 
differences in the geographical areas, case definitions, methodologies, and investigated 
samples used in different studies (Dionne et al., 2008; Hoy et al., 2012; McBeth & Jones, 
2007; H. Raspe, Matthis, Croft, & O'Neill, 2004; Tsang et al., 2008). In addition, the 
prevalence of BP and CBP (Harkness, Macfarlane, Silman, & McBeth, 2005; D. K. Weiner, 
Kim, Bonino, & Wang, 2006) and the demand for consultation and treatment are increasing 
(H. I. Andersson, Ejlertsson, Leden, & Scherstén, 1999; Freburger et al., 2009). The 
increases in prevalence might be due to the aging of the population (Ahacic & Kåreholt, 
2010; Hoy et al., 2012). However, there are many other factors that might account for this 
increase, such as increased reporting behavior, higher awareness of pain, or more/higher 
risk factors for reporting, such as psychological distress, the possibility of receiving 
compensation claims, etc. (Harkness et al., 2005; H. Raspe & Kohlmann, 1994).  
Chronic pain is characterized by its high persistence. Studies with 1- to 12-year follow-up 
periods showed that 75% to 90% of patients with chronic pain as well as patients with CBP 
had persistent pain. Higher severity, higher distress, and higher pain extent were associated 
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with lower recovery rates (H. I. Andersson, 2004; Bergman, Herrström, Jacobsson, & 
Petersson, 2002; McBeth, Macfarlane, Hunt, & Silman, 2001). Moreover, many variables 
have been identified as associated with the onset, chronicity and spread of pain. Several 
variables that are consistently observed are age, female sex, education, and the spatial 
extent of the pain (H. I. Andersson, 2004; Cimmino et al., 2011; Hoy et al., 2012). Therefore, 
research on the prevalence of CBP in Germany using comprehensive approaches is 
necessary. This research should also account for psychological distress (H. Raspe, Hüppe, 
& Matthis, 2003) because mental co-morbidities are associated with the onset and 
persistence of pain (Gureje, Simon, & Von Korff, 2001; McBeth et al., 2001). 
2.3 Chronic musculoskeletal pain and mental disorders
Studies of mental co-morbidity in patients with CBP performed in the 1980s were an 
important first step in demonstrating a strong relationship between chronic pain and 
psychological factors (Fishbain, Goldberg, Labbe, Steele, & Rosomoff, 1988; Katon, Egan, & 
Miller, 1985; Reich, Rosenblatt, & Tupin, 1983). Subsequent research confirmed the reported 
association. For example, it was suggested that approximately 65% of patients with 
depression have pain symptoms, and 18-85% of patients with pain have depression 
(depending on the pain condition and the study population; Bair, Robinson, Katon, & 
Kroenke, 2003).  
Chronic musculoskeletal pain has also been found to be associated with a higher prevalence 
of mental disorders in general. Patients with CBP (Demyttenaere et al., 2007; Patten, 
Williams, & Wang, 2006) and CWP (Benjamin, Morris, McBeth, Macfarlane, & Silman, 2000) 
suffer from mental disorders significantly more frequently than pain-free controls. The 
prevalences of current Axis-I mental disorders ranged from approximately 30% to 75% in 
CBP patients compared to approximately 20% in the general population (Jacobi et al., 2004; 
Wittchen et al., 2011), excluding somatoform pain disorder (Härter et al., 2002; Thieme, Turk, 
& Flor, 2004). The most common mental co-morbidities are mood disorders, anxiety 
disorders and substance-related disorders (Härter et al., 2002; Knaster, Karlsson, Estlander, 
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& Kalso, 2012), consistent with data from the general population (Jacobi et al., 2004; 
Wittchen et al., 2011).  
In a group of musculoskeletal pain patients, the current prevalence rates of anxiety, mood, 
and substance-related disorders (excluding nicotine dependence) were 15%, 10.7%, and 
2%, respectively (Härter et al., 2002; general population: 9%, 6%, and 3%, respectively; 
Jacobi et al., 2004). Life-time prevalence rates were reported as 33.5%, 32.5%, and 9%, 
respectively (Härter et al., 2002; general population: >14.5%, 18.6%, and 10%, respectively: 
Jacobi et al., 2004). The frequency of Axis-II personality disorders in chronic pain patients 
are inconsistent (Dersh, Polatin, & Gatchel, 2002) with reported prevalence rates ranging 
from approximately 9% to 60% (Kinney, Gatchel, Polatin, Fogarty, & Mayer, 1993; Thieme et 
al., 2004).  
The association of CBP and mental co-morbidities also has clinical implications. Co-morbid 
depression is associated with more pain complaints, more frequent pain episodes, a longer 
duration of pain, more intense pain, more days out of work, higher hospitalization rates and 
greater health care utilization (Bair et al., 2003).  
Furthermore, mental disorders are also of interest in the transition from (sub-acute) BP to 
CBP. First-onset BP is more likely to progress to CBP in men who have been diagnosed with 
major depression, GAD, or PTSD at some time in their lives (OR = 4.99, 2.45, and 3.23, 
respectively; Shaw et al., 2010). Moreover, the current and lifetime prevalence rates of 
depression and anxiety disorders are higher in CBP patients than in sub-acute BP patients 
(Kinney et al., 1993).  
Mental co-morbidity is also of interest in the spread and generalization of CBP. The odds 
ratio for psychiatric disorders in CWP compared to non-CWP patients is 3.18 (Benjamin et 
al., 2000), and the current prevalence rates for psychiatric disorders are 16.9% in CWP 
compared to 6.5% in CLP (Benjamin et al., 2000). Conversely, pain characteristics also 
influence mental co-morbidity. Current pain intensity was associated with higher odds of 
mental disorders (Knaster et al., 2012). These findings suggest that mental disorders are 
specifically associated with chronic pain and that research should target this association. It is 
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of special interest to determine whether this association also holds in non-selective, 
population-based samples. The complex association of CBP and mental co-morbidity 
demands mechanism-based approaches that might account for this complexity.  
2.4 Mechanism-based theories of chronic musculoskeletal pain
The etiology and pathogenesis of chronic musculoskeletal pain are still mainly unknown. 
Moreover, there is evidence suggesting that subgroups of CBP patients may differ in terms of 
etiopathology, clinical symptomatology, and psychophysiological patterns. The heterogeneity 
of CBP patients (Natvig et al., 2001; A. Raspe et al., 2003) is supported by the finding that 
the same disease can arise from various pathophysiological mechanisms. Conversely, the 
same pathophysiological mechanism may be relevant to distinct diseases (C. Maier et al., 
2010). This could explain differences in responses to the same treatments in patients with 
the same disease (C. Maier et al., 2010; Woolf & Mannion, 1999). Consequently, these 
subgroups should be treated with specific mechanism-based approaches, but to date, they 
have been treated with the same non-specific multimodal treatment programs, which often 
have only minor success (Karjalainen et al., 2009; Machado et al., 2009; O'Brien et al., 
2010). 
One of the most promising approaches to understanding CBP pathogenesis addresses the 
role of the central nervous system (CNS). Many techniques have been applied to detect 
abnormalities in the CNS, including quantitative sensory testing (QST; Dadabhoy, Crofford, 
Spaeth, Russell, & Clauw, 2008). QST is a method used to assess somatosensory function. 
A comprehensive QST protocol permits the determination of pain and detection thresholds 
and the discrimination of local vs. generalized and peripheral vs. central nervous 
mechanisms (Rolke et al., 2006). QST aberrations including signs of abnormal central 
nervous pathway function have been found in CBP. For example, studies have reported low 
pain thresholds and pain tolerance values in patients with CBP (Flor, Diers, & Birbaumer, 
2004). Another aspect of the psychobiology of pain is descending pain inhibition. It was 
found that pain inhibition is deficient in patients with different pain conditions (King et al., 
13 
2009; Leonard et al., 2009; Normand et al., 2011). Both somatosensory processing and pain 
inhibition might also be influenced by mental disorders (de Souza, Potvin, Goffaux, Charest, 
& Marchand, 2009; Klauenberg et al., 2008; Moeller-Bertram, Keltner, & Strigo, 2012). 
One important variable that has been associated with pain processing and pain inhibition is 
physical activity. Physical activity represents an important therapeutic concept in chronic pain 
(Hassett & Williams, 2011; Hayden, van Tulder, Malmivaara, & Koes, 2011) and is a part of 
most pain treatment programs (Bundesärztekammer (BÄK), Kassenärztliche 
Bundesvereinigung (KBV), & Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen 
Fachgesellschaften (AWMF), 2010; Themenheft, 2012). Different mechanisms underlying 
physical activities effects on pain have been proposed to be involved (Koltyn, 2000; Koltyn & 
Umeda, 2006). There is consistent evidence that pain perception is reduced for a limited 
period of time following an episode of intense exercise (so-called ”acute exercise-induced 
analgesia”; Koltyn, 2000; Kosek & Lundberg, 2003). It has been theorized that physical 
activity activates some generalized endogenous pain-modulatory mechanisms, such as 
conditioned pain modulation (CPM; formerly termed “diffuse-noxious-inhibitory-control”; 
Boecker et al., 2008; Koltyn, 2000). Moreover, a deficit in this system is associated with 
chronic widespread pain (CWP; Normand et al., 2011). However, the mechanisms of long-
term changes in pain processing due to physical activity remain unclear.  
The major hypothesis underlying the mechanism-based diagnosis in chronic pain syndromes 
is that defined symptoms and signs reflect possible underlying neurobiological mechanisms 
(Jensen & Baron, 2003; Woolf & Mannion, 1999). Therefore, the psychobiological 
assessment of CBP may detect common underlying pathophysiological changes. This might 
foster the development of mechanism-based treatment options and will impact the medical 
care of pain patients. Therefore, the assessment of chronic pain and research to identify 
factors associated with the development, maintenance, and spread of chronic pain, including 
their neurobiological correlates, is highly relevant. For example, this research may include 
studies of differences and commonalities of different subgroups of patients with CBP and the 
effects of preventative and therapeutic treatments such as regular physical activity.
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3. Publications
3.1 Study 1: The prevalence of chronic non-specific 
musculoskeletal pain and the role of the spatial extent of the pain
Gerhardt, A., Hartmann, M., Blumenstiel. K., Tesarz, J., & Eich, W. (in review)
Two major problems arise when CBP research is discussed. First, much of the information 
about BP has been gathered in clinical studies and is thus applicable only to a highly 
selected population. The authors therefore conclude that there is an urgent need for surveys 
on CBP in a representative population-based sample. Second, in most cases, CBP is only 
one aspect of a more complex syndrome that consists of additional pain and other symptoms 
(Natvig et al., 2001; A. Raspe et al., 2003). This is consistent with the bio-psychosocial 
perspective, which proposes that BP is associated with other pain and somatic symptoms as 
well as with social and psychological factors (Gatchel et al., 2007; Hancock, Maher, Laslett, 
Hay, & Koes, 2011; Kikuchi, 2008; H. Raspe et al., 2003). Therefore, it is important to 
consider the extent of pain and co-morbidities as well as correlates of chronic 
musculoskeletal pain conditions. 
Population-based data on CBP in general is available, but these data are typically based on 
questionnaire results. Thus, it is not possible to determine whether patients suffer from 
specific causes of CBP or from non-specific pain. Moreover, there is a lack of current data on 
the prevalence of CBP in representative population-based samples in Germany.   
The aim of our study was therefore to determine the prevalence of non-specific CBP in the 
general population of southwest Germany. Because the group of chronic musculoskeletal 
pain patients is reported to be heterogeneous (Natvig et al., 2001; A. Raspe et al., 2003), we 
also consider variables that might be associated with pain extent. Therefore, we combined 
the advantages of a population-based approach with those of clinical examination-based 
studies to enhance the validity of our findings and to overcome the limitations of prior 
research (Gerhardt, Hartmann, Blumenstiel, Tesarz, & Eich, in review).  
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We contacted 4000 representative inhabitants of southwest Germany by mail. Of the 
responders, 427 subjects suffered from CBP. With respect to the general population of 
southwest Germany, the age- and sex-adjusted prevalence rates for CBP and chronic 
widespread pain (CWP) were 17.7% and 6.7%, respectively. Other studies have reported 
prevalence rates for CBP ranging from 10% (Freburger et al., 2009) to 27% (Picavet & 
Schouten, 2003; B. H. Smith et al., 2004). Thus, the prevalence of CBP found in our study 
ranks in the middle of the previously reported range. The prevalence of CWP found in our 
study was relatively low (Gran, 2003; Staud, 2009; Wolfe, Ross, Anderson, Russell, & 
Hebert, 1995) compared with those in previous reports. The differences in the reported 
prevalence rates can be explained by the different definitions of CBP and methodologies 
used in different studies. 
Our data corroborates the assumption that the group of chronic pain patients is 
heterogeneous in terms of pain extent (Natvig et al., 2001). For example, persons referred to 
as having CLP can have pain in a single circumscribed area or pain affecting one entire half 
of the body. Therefore, the commonly used categorization of CLP vs. CWP is inadequate. 
We developed a pain drawing classification system to measure the extent of pain from a 
clinical point of view in a standardized manner to address this neglected issue. We 
subdivided the CLP and CWP groups into two groups each, depending on the extent of pain 
affecting the spine and the limbs (see caption of Figure 2.). Only 19.6% of those with CBP 
were categorized as having strict local pain (SLP), 42.1% reported chronic regional pain 
(CRP), 24.3% reported common chronic widespread pain (CoCWP), and 13.9% reported 
extreme chronic widespread pain (ExCWP). 
This finding has clinical implications. CBP is typically treated as a distinct disease. This 
approach seems artificial because almost 40% of the CBP subjects fulfilled the criteria for 
CWP, and only 19.6% had pain in the back only. This might contribute to the low treatment 
success. That most patients report pain in more than one body location is in line with the 
results of other studies (Carnes et al., 2007; Natvig et al., 2001; Picavet & Schouten, 2003), 
although extremely extensive pain is rare (Carnes et al., 2007). Thus, results that refer to 
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CBP must be interpreted with caution when observed in isolation from concomitant 
symptoms.  
Instead, bio-psychosocial models that account for the amplification of CBP into a broader 
syndrome that involves pain elsewhere, other somatic symptoms, psychological factors, and 
social and occupational context seem to be more appropriate (Hancock et al., 2011; Kikuchi, 
2008; H. Raspe et al., 2003).  
To account for the bio-psychosocial model we evaluated the associations of our four pain 
extent groups with sociodemographic variables and overall clinical context. Our findings are 
consistent with those of other studies, which have shown that increased pain extent is 
associated with female gender (Gran, 2003; Staud, 2009; Wolfe et al., 1995), a higher rate of 
applications for disability pensions (Kamaleri, Natvig, Ihlebaek, & Bruusgaard, 2009), higher 
pain severity, and greater impairment (Carnes et al., 2007; Wenngren & Stålnacke, 2009). 
Moreover, greater extents of pain were associated with more medical consultations and 
greater pain medication use.  
In conclusion, our data show that CBP is prevalent and that pain is not restricted to the back 
in most individuals with CBP. This challenges the concept of CBP as a distinct entity. Our 
proposed four-group classification system that links the extent of pain with sociodemographic 
and clinical variables was able to subdivide the patients in distinct groups. This underscores 
the utility of classifying pain patients according to pain extent. Clinically, the developed 
classification system can be used to identify highly distressed/burdened subjects that might 
be responsible for a large share of the costs associated with CBP. In addition, physicians 
should pay closer attention to clinical variables other than pain extent, especially in patients 
with more extensive spread of pain. As we showed, this group has also higher rates of 
mental co-morbidity. Due to the high prevalence of mental disorders in chronic pain patients, 
as was observed in our sample, we decided to use the SCID as the gold standard for the 
assessment of mental disorders in the second study. Due to the observed heterogeneity of 
sociodemographic variables and clinical profiles of these CBP patients, we tested whether 
there is also psychophysiological heterogeneity within the CBP group in the third study. 
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Figure 2. The four classes of pain extent in the new suggested classification system. Chronic local pain (CLP) 
and chronic widespread pain (CWP; for classification see Figure 1) were each subdivided. a) Strict back pain: 
pain in 1 to 3 spinal areas, no further pain. b) Chronic regional pain: pain in the spinal area plus additional pain, 
but criteria for CWP not fulfilled. c) Common CWP: pain in the spinal area plus at least two contralateral limbs but 
not all four limbs. d) Extreme CWP: all spinal areas and all four limbs.
c d
a b
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3.2 Study 2: Chronic non-specific musculoskeletal pain and mental 
disorders
Gerhardt, A., Hartmann, M., Schuller-Roma, B., Blumenstiel, K., Bieber, C., Eich, W., 
& Steffen, S. (2011).
Patients with CBP are more likely to suffer from mental disorders than are pain-free 
individuals (Demyttenaere et al., 2007; Uguz et al., 2010). However, the prevalence of 
mental co-morbidities is sample dependent (Bair et al., 2003), and few data related to the 
prevalence of mental co-morbidities in CBP patients in Germany are available. Moreover, 
mental co-morbidity in CBP is often assessed through questionnaires. This limits the validity 
of the results because most questionnaires include both somatic and vegetative signs 
(Fishbain, Cutler, Rosomoff, & Rosomoff, 1997). Thus, diagnoses of many disorders and 
chronic pain might be confounded.  
The aim of this study was to investigate the prevalence and types of mental co-morbidities in 
a well-characterized, representative population-based sample of subjects with non-specific 
CBP (Gerhardt et al., 2011). The main advantage of our approach was that individuals with 
CBP were drawn from the general population rather than from a specific clinical setting. The 
second strength was the simultaneous assessment of Axis-I and -II disorders in a validated 
clinical interview. The third advantage was the use of a physical examination to ensure that 
the diagnosis of non-specific CBP was not based on patient self-reports, as is common.  
In our population-based sample of 4000 inhabitants of the Rhein-Neckar-Kreis (see study 1), 
we randomly selected 50% of the subjects for a Structured Clinical Interview for DSM-IV 
(SCID). The SCID-I + II was used to assess current (within the previous four weeks) mental 
co-morbidity and was completed by 110 subjects with non-specific CBP.  
Of the subjects with CBP, 39 (35.5%) received at least one current Axis-I diagnosis, 
excluding somatoform pain disorders. Anxiety disorders (20.9%) and affective disorders 
(12.7%) were the most frequent diagnoses, followed by substance-related disorders (7.3%) 
and eating disorders (5.5%).  
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The prevalence of at least one Axis-II personality disorder (PD) was 15.5%. The most 
frequent diagnoses were obsessive-compulsive and avoidant PD (4.5% each), followed by 
borderline PD (3.6%), paranoid PD (2.7%) and narcissistic PD (0.9%). Thus, diagnoses in 
Cluster C (anxious or fearful disorders) were the most prominent and were found in 9.1% of 
subjects. 
When the psychopathological aspects of both Axes are considered together, a consistent 
tendency towards vulnerability to anxiety, fear and avoidance was observed among our 
subjects, as reported elsewhere (Malmgren-Olsson & Bergdahl, 2006). Sensitivity to anxiety 
can be viewed as a precursor to pain-related fear or depression; avoidance behavior or 
disability is thought to be a response to pain (Alschuler, Theisen-Goodvich, Haig, & Geisser, 
2008; Murphy, Lindsay, & De C Williams, 1997; Vlaeyen & Linton, 2000). Furthermore, 
avoidance may contribute to the maintenance or exacerbation of chronic pain and produce a 
number of additional negative physical and psychological symptoms. Fearful people are 
more conscious of possible threatening signals and are therefore less able to shift their 
attention away from pain-related information (Vlaeyen & Linton, 2000). Additional longitudinal 
studies are needed to better characterize the role of anxiety in chronic pain. 
The prevalence rates found here rank at the lower end of the previously reported range of 
mental co-morbidity rates in subjects with CBP (Atkinson, Slater, Patterson, Grant, & Garfin, 
1991; Dersh, Gatchel, Polatin, & Mayer, 2002; Katon et al., 1985; Polatin, Kinney, Gatchel, 
Lillo, & Mayer, 1993). However, the prevalence of Axis-I disorders remains significantly 
elevated compared to that in the general population (OR 2.23, p < 0.001; Jacobi et al., 2004). 
The prevalence of Axis-II disorders is comparable to that found in the general population (W. 
Maier, Lichtermann, Klingler, Heun, & Hallmayer, 1992). Other studies are consistent with 
our findings of a significantly higher, albeit still moderate, prevalence of mental co-morbidity 
in patients with CBP (31%-38%; Härter et al., 2002; Joukamaa, 1991; Mayr, Högler, 
Ghedina, & Berek, 2003; Von Korff et al., 2005).  
The most frequent mental co-morbidities that we reported were anxiety disorders (20.9%). In 
contrast, others have reported that affective disorders are the most frequent mental co-
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morbidities in patients suffering from pain (Kinney et al., 1993; Polatin et al., 1993). The 
finding that anxiety disorders were the most prevalent might be due to our population-based 
setting, as confirmed by other population-based studies (McWilliams, Cox, & Enns, 2003; 
Stang et al., 2006; Von Korff et al., 2005) and consistent with data from the general 
population (Jacobi et al., 2004). It can be hypothesized that depressed patients tend to be 
identified more easily in the medical system than are patients with anxiety disorders because 
patients with depression are more likely to seek help than are patients with anxiety disorders 
(Essau, Conradt, & Petermann, 2000; Henderson, Pollard, Jacobi, & Merkel, 1992).  
The recognition of anxiety, fear and avoidance may be well established in research literature 
and in specialized pain centers. However, our population-based setting also captures 
patients with low to moderate pain intensity and those with low help-seeking behavior. These 
patients also suffer from mental co-morbidities, and failing to recognize this fact may foster 
chronification. Moreover, rehabilitation may be compromised if concurrent psychiatric 
disorders are not recognized and adequately treated (Dersh et al., 2007; Gatchel, 1996).  
Therefore, we recommend that a standardized screening for and assessment of mental 
disorders be implemented in conjunction with the initial pain assessment and at regular 
intervals. This should also be conducted in primary care settings, not only in research or 
specialized pain centers. This might help to reduce the high number of untreated patients 
who may be reluctant to seek help in overcoming pain due to their anxiety disorder. 
3.3 Study 3: Somatosensory (mechanism-based) aspects of chronic 
non-specific musculoskeletal pain 
Blumenstiel, K., Gerhardt, A., Rolke, R., Bieber, C., Tesarz, J., Friederich, H.-C., 
Eich, W., & Treede, R.-D. (2011).
Due to the observed heterogeneity of CBP patients (e.g., in study 1) and insufficient 
treatment success, we tested whether there are also psychophysiological differences 
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between distinct subgroups of CBP patients (Blumenstiel et al., 2011). Such findings might 
have implications for treatment and potentially improve treatment success.  
Research has revealed certain alterations in the central nervous system that lead to greater 
pain sensitivity in both CBP and fibromyalgia syndrome (FMS; CWP plus tenderness in 
specified regions; Arendt-Nielsen & Graven-Nielsen, 2003; Desmeules et al., 2003). 
However, it is unclear whether CBP and FMS subjects show the same or different 
alterations. Therefore, the aim of this study was to identify commonalities and differences in 
the pathophysiologies of CBP and FMS.  
We used the German Research Network on Neuropathic Pain (DFNS) QST protocol to 
obtain comprehensive profiles of somatosensory function. The protocol comprised thermal 
and mechanical detection and pain thresholds, vibration thresholds, and pain sensitivity to 
sharp and blunt mechanical stimuli (Rolke et al., 2006). We studied 21 FMS patients, 23 CBP 
subjects, and 20 healthy controls (HC). Each subject underwent the battery of tests on the 
back (pain site) and on the dorsal hand (pain-free control site).  
The FMS group showed significantly increased mechanical and thermal pain sensitivity (with 
the exception of HPT over the hand dorsum) compared to the CBP and HC groups, whereas 
detection sensitivity was not increased. Our sensory profile suggests that hyperalgesia in 
FMS may involve all nociceptive submodalities. Moreover, pain sensitivity was increased 
over the back and hand dorsum (parallel profiles for back and hand; Figure 3a). Thus, the 
increased sensitivity in FMS is generalized in space (superficial and deep pain, back and 
hand) and across nociceptive submodalities, but not to other somatosensory functions. 
The best possible explanation for such generalized hyperalgesia is a deficiency in the pain 
inhibitory system (Villanueva & Le Bars, 1995). The term “central sensitization”, often used in 
the context of FMS (Desmeules et al., 2003; Price & Staud, 2005), does not sufficiently 
describe the clinical picture. This term implies an increased excitability of the central 
neurons, but its effects are restricted in space to the receptive fields and often limited to 
mechanical test stimuli (Treede, Handwerker, Baumgärtner, Meyer, & Magerl, 2004; Treede, 
Meyer, Raja, & Campbell, 1992). Disinhibition, in contrast, strikes the entire body and may be 
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adequate to explain a generalized pain syndrome such as FMS. Thus, the role of 
disinhibition should be addressed in future studies (Pud, Granovsky, & Yarnitsky, 2009; 
Yarnitsky et al., 2010).  
We found an increased pressure pain sensitivity and lower vibration sensitivity on the back, 
but no significant differences in the dorsum of the hand, in sample of CBP subjects 
compared to HCs. Increased PPT sensitivity primarily reflects muscle nociception and 
peripheral sensitization (Kilo, Schmelz, Koltzenburg, & Handwerker, 1994; Kosek, Ekholm, & 
Hansson, 1999). The restriction of sensitization to the painful area in the back means that 
there were no signs of pain generalization (Figure 3b). These results suggest localized 
changes in the muscles and joints. There was no evidence for central sensitization or 
disinhibition in our sample of CBP subjects, indicating that chronic pain per se is not 
sufficient to indicate these abnormalities.  
This finding is intriguing because other authors (Giesecke et al., 2004) have suggested that 
central sensitization is involved in both FMS and CBP. Because our CBP sample was drawn 
from the general population, widespread pain sensitivity observed in pain clinic patients may 
not be representative of all patients with CBP. Therefore, parameters other than chronic 
Figure 3a. QST profiles in fibromyalgia syndrome 
patients. Circles: hand, triangles: back. Filled symbols: 
significant difference from healthy controls (open 
symbols: n.s.; t test). *P < 0.05, **P < 0.01, ***P < 
0.001, paired t test of hand versus back. Parallel 
profiles between hand and back indicate generalized 
sensory changes. CDT, cold detection threshold; CPT, 
cold pain threshold; HPT, heat pain threshold; MDT, 
mechanical detection threshold; MPS, mechanical pain 
sensitivity; MPT, mechanical pain threshold; PPT, 
pressure pain threshold; TSL, thermal sensory limen; 
VDT, vibration detection threshold; WDT, warm 
detection threshold; WUR, wind-up ratio; values are 
mean±SEM.  
Figure 3b. QST profiles in chronic back pain patients. 
Circles: hand, triangles: back. Filled symbols: 
significant difference from healthy controls (open 
symbols: n.s.; t tests). *P < 0.05, ***P < 0.001, paired t 
test hand versus back. Significant differences indicate 
that sensory changes are localized to the back. 
Abbreviations are defined in the legend to Figure 3a. 
Values are mean±SEM.  
Figure 3 a and b: Reproduced from the Clinical Journal 
of Pain (volume 27, number 8, pages 682-690), with 
permission from Walters Kluwer Health. 
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ongoing nociceptive pain are likely to be predisposing factors for widespread pain and FMS. 
Such factors may include pain intensity, the subtype of CBP, and psychosocial factors, which 
were investigated in study 1 and 2.  
In summary, FMS and CBP subjects exhibit distinct sensory profiles. This finding 
underscores that CBP patients are heterogeneous with regard to not only sociodemographic 
and clinical variables but also psychophysiological measures. This is consistent with the 
main hypothesis of a mechanism-based diagnosis in chronic pain syndromes, which 
proposes that defined symptoms and signs reflect possible underlying neurobiological pain 
mechanisms (Jensen & Baron, 2003; Woolf & Mannion, 1999). Based on these findings and 
the suggested role of the descending pain modulatory system in the observed alterations, we 
designed study 4. Study 4 addresses a protective/curative factor, physical activity. Physical 
activity is a major component of the treatment for chronic musculoskeletal pain, and 
descending pain modulation is discussed as a potential factor in its efficacy.  
3.4 Study 4: Evaluation of physical activity as a mechanism-based 
concept 
Tesarz, J., Gerhardt, A., Schommer, K., Treede, R.-D., & Eich, W. (2013). 
Regular physical activity is recommended in many chronic musculoskeletal pain treatment 
guidelines (BÄK, KBV, & AWMF, 2010; Themenheft, 2012). However, although there is 
consistent evidence that pain perception is reduced for a limited time period following an 
episode of intense exercise (Koltyn, 2000), the effect of regular physical activity on long-term 
changes in pain perception and pain processing at rest is inconsistent. A meta-analysis to 
which the author of this doctoral thesis contributed concluded that athletes possess higher 
pain tolerance than normally active controls, whereas the available data on pain threshold 
are less uniform (Tesarz, Schuster, Hartmann, Gerhardt, & Eich, 2012). However, there was 
a high heterogeneity between the included studies, possibly due to the different pain 
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induction methods and heterogeneous study groups used. Moreover, the underlying 
mechanisms remain largely unclear. 
Therefore, we conducted a study to identify differences and commonalities in pain perception 
and pain processing at rest between athletes (n = 25) and normally active controls (n = 26). 
Our study is the first to assess pain perception in athletes using a comprehensive 
standardized and validated pain assessment protocol (QST) and an objective evaluation of 
physical fitness (VO2max; Tesarz, Gerhardt, Schommer, Treede, & Eich, 2013). We also 
evaluated the endogenous pain modulating system to investigate a potential underlying 
mechanism (conditioned pain modulation, CPM; i.e., the diffuse-noxious-inhibitory-control-
like effect). CPM was measured using two tonic heat pain stimuli separated by a 2-min cold 
pressor task (CPT; conditioning stimulus). The theory behind is that pain inhibits subsequent 
pain by activating the descending pain modulatory system (Le Bars, Dickenson, & Besson, 
1979a, 1979b). CPM is quantified by subtracting the pain ratings given before the CPT from 
those given after the CPT. Negative values indicate CPM activity. 
We observed an increased mechanical pain threshold and an increased sensitivity to 
vibration in the athletes. No significant differences were found for heat, cold or pressure pain 
thresholds or for temperature and mechanical detection thresholds.  
These findings are consistent with previous work, which also showed no differences for heat 
(L. Smith, 2004; Sternberg, Bailin, Grant, & Gracely, 1998) or pressure pain thresholds 
between athletes and normally active controls (Manning & Fillingim, 2002; Ryan & Kovacic, 
1966). The isolated loss of function for pinprick stimuli described in this study is particularly 
interesting because MPT by pinprick has not been tested previously in athletes. An increase 
in MPT can be caused by either denervation of the peripheral nociceptors or inhibition within 
the central nervous system (Treede & Magerl, 2000; Ziegler, Magerl, Meyer, & Treede, 
1999). Even if only MPT and VDT differed significantly between the groups, it is worth noting 
that except for vibration, all QST parameters showed a general tendency toward a reduced 
sensitivity indicating a ’loss of function‘.   
The increased sensitivity to vibration is an interesting finding because the vibration detection 
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threshold was the only measure that exhibited a gain of function (more sensitive perception). 
There is evidence that vibration perception is associated with postural control (Kristinsdottir, 
Fransson, & Magnusson, 2001; Kristinsdottir, Jarnlo, & Magnusson, 1997). Postural control 
is an important feature of athletic competence, and enhanced vibration sensitivity may be the 
result of a well-trained locomotive system. However, this explanation is rather speculative, 
and further research is needed to better understand the underlying mechanisms. 
Another important finding was that CPM was different in athletes and normally active 
controls. Interestingly, athletes were characterized by a significantly lower activation of the 
CPM by the CPT than were normally active controls. One possible explanation for this 
phenomenon may be an elevated activation level of the endogenous pain inhibitory system in 
athletes. This continuously heightened activation level of endogenous pain inhibition may 
impede additional activation by the CPT. This ‘elevated activation-level hypothesis’ to 
describe the inhibitory pain control in athletes is consistent with our observation that all QST 
parameters, except VDT, showed a general trend of reduced sensitivity in the athletes. 
However, there are also other promising explanations, such as a shift in the activation 
threshold of the endogenous pain inhibitory system in athletes. The ‘threshold hypothesis’ 
postulates that the pain inhibitory system in athletes requires stronger stimuli for activation or 
that – using fixed stimulus intensity – the same stimulus will result in a lower activation of the 
pain inhibitory system in these subjects.  
The specific mechanism underlying alterations of pain perception at rest in athletes cannot 
be clarified in detail based on these findings alone, but our data suggest that the endogenous 
pain inhibitory system may be less responsive in athletes. Further research should be 
conducted to investigate the underlying mechanisms in greater detail, including longitudinal 
studies that address this “chicken and egg” question. 
Study 5 will combine clinical variables and psychophysiological measures because we 
showed that CBP patients exhibit differences in both types of variables. Moreover, the 
investigation of the association between clinical context/symptoms and psychophysiological 
measures is a strong candidate subject for a comprehensive approach.
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3.5 Study 5: Research agenda on mechanism-based concepts in 
chronic non-specific musculoskeletal pain 
Gerhardt, A., Hartmann, M., Tesarz, J., Janke, S., Leisner, S., Seidler, G., & Eich, W. 
(2012). 
The establishment of a mechanism-based subgroup classification of pain and the 
development of associated specific treatments were suggested more than a decade ago 
(Woolf et al., 1998). Since then, the topic has been controversial (Jensen & Baron, 2003; 
Turk, 2005; Wand & O'Connell, 2008; Woolf & Mannion, 1999). The small effect sizes of 
chronic pain treatments were suspected to be due to non-specific treatment approaches that 
could not address many different pain generating and maintaining mechanisms (C. Maier et 
al., 2010; Woolf & Mannion, 1999). This is also supported by clinical experience, which 
shows that the subgroups of chronic pain patients are heterogeneous despite suffering from 
the same disease, i.e., non-specific CBP. 
Study 1 and 2 showed that the group of CBP patients is heterogeneous and that patients 
differ in many sociodemographic and clinical variables (Gerhardt et al., in review; Gerhardt et 
al., 2011). Study 3 added that the group of CBP patients is also heterogeneous in terms of 
psychophysiological patterns (Blumenstiel et al., 2011). Study 4 showed that behavioral 
aspects are associated with psychophysiological changes in pain perception and pain 
processing, suggesting that the psychophysiological differences due to factors in addition to 
different pain characteristics (Gerhardt et al., 2012). In summary, our studies validate the 
hypothesis that that chronic musculoskeletal pain patients are heterogeneous due to the 
number of mechanisms involved in chronic pain.  
These findings support the assumptions of mechanism-based approaches in CBP. The 
identification of patient subgroups is necessary to establish distinct pathophysiological 
mechanisms and targets for mechanism-based treatment options. However, only a few 
studies have aimed to identify different pain mechanisms (Blumenstiel et al., 2011; C. Maier 
et al., 2010), and those studies have predominantly focused on the general aspects of pain 
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processing, thus neglecting the heterogeneity of patients with musculoskeletal pain. 
Consequently, there is a need for studies that comprise a multitude of the mechanisms that 
are potentially involved in the chronicity and spread of pain.  
We developed a theoretical framework (Figure 4) that accounts for many of the variables that 
are of interest in chronic pain. In the current study, we consider this comprehensive 
framework in addition to the mental co-morbidities and psychophysiological patterns that we 
have studied previously. Thus, we link sociodemographic and clinical variables with 
neurobiological observations to account for the heterogeneity of CBP patients. Consequently, 
specific mechanism-based subgroups of pain patients should be identified and eventually 
matched to specific mechanism-based treatment options (Gerhardt et al., 2012).  
Figure 4. Theoretical framework. 
Our research is novel in its comprehensive approach and its use of reliable and valid 
diagnostic tools. This approach comprises many variables that have been shown to be 
involved in changes in sensory processing. This comprehensive approach, which combines 
clinical manifestations and neurobiological variables, will foster research on CBP and the 
treatment of CBP patients. 
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4.0 Summary and conclusions
CBP is widespread and is associated with a high burden to the patient and immense costs. 
However, CBP treatments are typically unsuccessful. This might be due to the use of 
nonspecific treatment options that do not account for the heterogeneity among CBP patients. 
In addition, research on CBP is typically based on highly selected samples, often relies on 
data gathered from questionnaires rather than interviews or examinations, and usually 
neglects the heterogeneity of patients. This might lead to biases.  
Therefore, we conducted several studies that combined the advantages of epidemiological 
and clinical research (e.g., the use of representative samples and more objective and valid 
data, respectively). These studies also accounted for patient heterogeneity, and, in a second 
step, tried to link the clinical manifestations and psychophysiological/pathophysiological 
mechanisms.  
Our results show that CBP is highly prevalent in the general population (17.7%; study 1) and 
is often associated with mental co-morbidities (35.5%; study 2). Individuals with CBP were 
twice as likely as individuals from the general population to suffer from a mental co-morbidity, 
with anxiety disorders as the leading disorder. We also confirmed the assumption that the 
group of CBP patients is heterogeneous. This was true for many sociodemographic and 
clinical variables (study 1) as well as psychophysiological variables (study 3). We also 
showed that physical activity, as a behavioral, preventative and curative method for CBP, is 
associated with changes in pain perception and pain processing (study 4). 
Our findings have implications for further research as well as treatment. The reported high 
prevalence of CBP will foster health services research to address the socioeconomic burden 
of CBP. Moreover, our results showed that pain drawings indicating the spatial extent of pain 
could be used to identify a highly burdened group of CBP patients with high health care 
utilization that require more detailed assessments of pain and associated variables. Our 
research also suggests that primary care physicians should assess patients with BP 
complaints for anxiety disorders to avoid exacerbating BP and to potentially prevent the 
spread and chronification of the pain. In addition, our results especially highlight the need for 
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more research on mechanism-based aspects of CBP to address the high heterogeneity of 
CBP patients and to link clinical manifestations with potential underlying pathophysiological 
mechanisms. This might foster the development of specific mechanism-based treatment 
options that might be more successful than the existing treatments. Our research shows that 
therapies should include physical activity, which is recommended in many CBP treatment 
guidelines.  
However, there are also some limitations to our studies. We did not account for all the 
complexities of CBP patients, which would require more comprehensive approaches (e.g., 
using the methods of studies 1 to 3 within one study). Moreover, one important challenge will 
be to account for the interactions of different variables (e.g., CBP and depression, CBP and 
anxiety, CBP and anxiety and depression); research has shown that those results might 
differ in patients who only satisfy one criterion (e.g., anxiety) rather than multiple criteria (e.g., 
anxiety and depression). This will require large sample sizes of patients and a 
comprehensive assessment of pain and associated variables. This is addressed within a 
current research project in which the author of this dissertation thesis is participating (study 
5). We also hope to encourage other researchers to confront this challenge, as well as to 
replicate our findings and address its limitations. 
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Figure 1: Flow-chart of subject inclusion  
Chronic back pain (CBP) was defined as pain in the back on at least 45 days within the last three months.  
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Figure 2: Heidelberg pain drawing mask. (a) Participants were given drawings of the body (front view and 
back view) and were asked to mark all of the painful areas of the body. (b) A transparent template indicates 
the boundaries of each region. It was placed over the pain drawings to assist in analysis.  
The regions are as follows: a) Cervical spine, b) Thoracic spine, c) Lumbar spine, and d) Limb.  
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Figure 3: Classification of pain extent into four groups according to the suggested new classification system. 
(a) Strict back pain: pain in 1 to 3 spinal areas, no further pain. (b) Chronic regional pain: pain in the spinal 
area plus additional pain, but criteria for CWP is not fulfilled. (c) Common CWP: pain in the spinal area plus 
at least two contra-lateral limbs, but less than four limbs. (d) Extreme CWP: all spinal areas and all four 
limbs are affected.  
190x181mm (600 x 600 DPI)  
 
 
Page 39 of 39
Official Journal of the American Academy of Pain Medicine
Pain Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
PSYCHOLOGY, PSYCHIATRY & BRAIN
NEUROSCIENCE SECTION
Original Research Article
The Prevalence and Type of Axis-I and
Axis-II Mental Disorders in Subjects
with Non-Specific Chronic Back Pain:
Results from a Population-Based Studypme_1190 1231..1240
Andreas Gerhardt, MA,* Mechthild Hartmann, MA,*
Bärbel Schuller-Roma, MD,* Klaus Blumenstiel,
MD,*† Christiane Bieber, MD,* Wolfgang Eich, MD,
PhD,* and Sabine Steffen, MA*‡
*Department of General Internal Medicine and
Psychosomatics, University Hospital, Ruprecht Karls
University, Heidelberg;
†Department of Psychosomatic Medicine and
Psychotherapy, Fürst-Stirum-Hospital, Bruchsal;
‡Department of Psychiatry and Psychotherapy II, BKH
Guenzburg, Ulm University, Guenzburg, Germany
Corresponding author: Andreas Gerhardt, MA,
Department of General Internal Medicine and
Psychosomatics, University Hospital Heidelberg,
Im Neuenheimer Feld 410, D-69120 Heidelberg,
Germany. Tel: 0049-6221-5636860; Fax:
0049-6221-568450; E-mail: andreas.gerhardt@
med.uni-heidelberg.de.
There are no conflicts of interest related to the
manuscript on the part of the authors.
Abstract
Objective. To investigate the prevalence and the
type of mental comorbidity in a population-based
sample of subjects with non-specific chronic back
pain.
Design. Representative population-based survey.
Setting. The city of Heidelberg (in southwestern
Germany) and 10 adjacent communities.
Patients. From a random sample of individuals
(N = 2,000), 1,091 subjects completed a question-
naire including a pain assessment. Of those, 188
subjects (17%) fulfilled the criteria for chronic back
pain ($45 days of back pain in the last 3 months)
and were subsequently invited to undergo a detailed
clinical examination; 131 subjects (70%) agreed to
participate. The Structured Clinical Interview for the
Diagnostic and Statistical Manual of Mental Disor-
ders IV (DSM-IV) (SCID-I + II) was used to assess
current (defined as the previous 4 weeks) mental
comorbidity and was completed in 110 subjects
(84%) with non-specific chronic back pain.
Intervention. N/A.
Outcome Measures. DSM-IV mental comorbidity
diagnoses.
Results. The overall prevalence of mental comor-
bidity of Axis-I and -II disorders were 35.5% and
15.5%, respectively. Of Axis-I disorders, anxiety dis-
orders (20.9%) and affective disorders (12.7%) were
the most frequent. Of Axis-II disorders, 9.1% of diag-
noses was of the Cluster C category (anxious/
inhibited). Compared with the general population,
the total rate of Axis-I comorbidity was significantly
higher, while the total rate for Axis-II personality
disorders was only slightly different.
Conclusions. The consistent diagnoses of anxiety,
fear, and avoidance in these subjects indicate that
also primary care health professionals should con-
sider anxiety disorders in patients with chronic pain,
in addition to the affective disorders that are most
frequently self-reported in pain patients.
Key Words. Non-Specific Chronic Back Pain (CBP);
Mental Disorders; Prevalence; SCID; Epidemiologic
Design; Mental Comorbidity
Pain Medicine 2011; 12: 1231–1240
Wiley Periodicals, Inc.
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Introduction
Today, pain of the musculoskeletal system is the most
common pain syndrome worldwide [1–3]. This type of
pain is on the increase and is of immense cost to the
public health system [4]. About one third of patients who
were treated at the primary care level had a predominance
of musculoskeletal pain [5]. Chronic back pain (CBP), a
major subgroup of musculoskeletal diseases, is of high
prevalence and patients often respond poorly to treatment
[6–8]. Therefore, research identifying various factors asso-
ciated with the development and maintenance of back
pain is highly relevant.
Empiric studies of the etiology of CBP have identified
somatic as well as psychological and social factors as
risks for developing a chronic condition [9,10]. Of these
variables, mental comorbidity is of interest. Several studies
found an increased prevalence of mental disorders in CBP
patients, ranging from 31% to 98% [11,12]. Reasons for
the high variability in prevalence include differences in
study design, instrumentation, or the quality of the collec-
tion of somatic and mental diseases [11].
A study by Polantin et al. found that 59% of CBP patients
demonstrated current symptoms of at least one Axis-I
diagnosis according to the DSM-IV and 51% met the
criteria for any Axis-II personality disorder (PD) [12]. Similar
high prevalence rates were found in other studies of
chronic musculoskeletal pain [13,14]. Differences in
patients with acute (23% Axis-I and 21% Axis-II disorders)
or chronic (68% Axis-I and 60% Axis-II disorders) low back
pain show that mental comorbidity may play an important
role in CBP [15]. In contrast, only about 15% of the
general population was identified as suffering from acute
mental disorders in the National Institute of Mental Health
Epidemiologic Catchment Area Survey [16].
In patients with CBP, affective disorders were the most
frequently reported diagnoses (32.4–68.0%), followed by
substance abuse (13.2–40.5%), and anxiety disorders
(10.6–19.0%) [12,14,17]. These results differ from repre-
sentative population-based samples, in which anxiety dis-
orders are the most prevalent (9.0–14.5%) [18]. In more
recent studies of chronic pain, there is some evidence that
anxiety disorders might occur as frequently as mood dis-
orders [19–21].
The studies mentioned above either were confined to
patients receiving clinical treatment, or had methodologi-
cal shortcomings. In fact, it is known that only half of the
individuals suffering from musculoskeletal pain seek treat-
ment through the medical system [22]. Therefore, the
purpose of the present study was to investigate the
prevalence and the type of mental comorbidity in a rep-
resentative population-based sample of individuals with
CBP. To reliable diagnose non-specific CBP subjects
were physically examined. The use of a clinical, standard-
ized assessment method (Structured Clinical Interview for
DSM-IV [SCID]; Axis-I + Axis-II) was used to yield reliable
information about the prevalence and the type of mental
disorders in a representative population of subjects with
CBP.
Methods
Design and Sample Selection
The study is part of a population-based longitudinal mul-
tiregional postal survey of back pain [23] by the German
Back Pain Research Network (GBPRN). Heidelberg and
10 adjacent communities were randomly chosen out of 55
cities and communities in the southwestern district (Rhein-
Neckar) of Germany. A random sample of 4,000 persons
was drawn from these communities, proportional to the
number of inhabitants.
To identify the sample, we asked the registration offices to
provide lists of inhabitants suitable for our requirements
(18–74 years old and residing in the chosen regions). This
procedure ensured that a representative sample of the
entire population was included. From a list of 4,000 indi-
viduals, 3,899 were reached by mail and were asked to fill
out a screening questionnaire that included questions
regarding the occurrence, intensity, duration, and radiation
of back pain, social and demographic variables, and psy-
chometric tests. Additionally, space was provided where
they could register their contact information (telephone
number and availability). If necessary, up to two reminders
were sent at 3- and 6-week intervals after the first mailing.
The questionnaires were returned by 2,408 individuals
(61.8%). The response rates were approximately 30%
after the first letter, approximately 20% after the first
reminder, and approximately 10% after the second
reminder.
All individuals suffering from back pain for $ 45 days
during the last 3 months (N = 427) were contacted by
telephone and invited to a clinical (physical and psycho-
logical) examination at the university outpatient depart-
ment. If no telephone number was available, individuals
were contacted by mail. If an individual was not reached
with the first call, he or she was recontacted up to five
times. If an appointment was missed, the individual was
called up to two more times to schedule a new appoint-
ment. A total of 303 individuals accepted the invitation for
a clinical examination.
To examine the prevalence and the type of mental comor-
bidity among non-specific CBP subjects, we administered
the SCID (SCID-I and SCID-II), a comprehensive and
highly valid instrument. Because of time and personnel
constraints, we initially randomly allocated half of the
population (2,000 out of 4,000 individuals) for the Struc-
tured Clinical Interview. Of the randomized subsample,
1,091 subjects returned the questionnaire; 198 of them
fulfilled the criteria for CBP. These 198 subjects were
invited to a physical examination in our outpatient depart-
ment to verify self-diagnosis of CBP and to exclude
patients with specific causes of CBP. Of those invited, 57
patients refused participation. The remaining 141 subjects
were examined (general, rheumatological and neurological
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examination, blood tests, past medical history, past
severe injuries) for specific causes of CBP. After the physi-
cal examination, 10 patients were excluded due to specific
causes of CBP (two suffered from Bechterew’s disease,
two suffered from rheumatoid arthritis affecting the spine,
one suffered from polymyalgia rheumatica, one suffered
from tumor/metastases, one suffered from spondelolysis,
three suffered from disc hernia). The remaining 131 sub-
jects with non-specific CBP were scheduled for the SCID
procedure (psychological examination). Fourteen of the
scheduled SCID interviews could not be completed for the
following reasons: an incomplete physical examination
(N = 4), exhaustion after the physical examination (N = 6),
refusal to participate in the study (N = 2), and lack of
language skills (N = 2). The detailed participation flow is
shown in Figure 1.
Overall, 117 individuals participated in the SCID interview,
but seven interviews were not included in the analysis
because the interview was incomplete or interrupted.
Thus, 110 interviews (84%) were evaluated.
The study was carried out in accordance with the Decla-
ration of Helsinki of 1975. The ethics committee of the
Medical Hospital of Heidelberg approved this study,
and all participants gave their written informed consent.
Participants received an allowance of EUR 10 ($14) for
attending the entire examination.
Assessment
To assess mental comorbidity, the German version of the
SCID, which consists of two parts, was used [24]. The
SCID-I is a semi-structured interview for the evaluation of
major DSM-IV Axis-I diagnoses. In this study, we used
the non-patient version. By using the SCID-I, it is pos-
sible to derive both a current and a previous history of
psychiatric illness. The category of somatoform pain dis-
order is highly controversial with respect to back pain.
Therefore, in accordance with other authors, we
excluded the diagnosis of somatoform pain disorder
[14].
Figure 1 Participation flow, including SCID subsample. SCID = Structured Clinical Interview for DSM-IV.
1233
Mental Disorders in Non-Specific Chronic Back Pain
The SCID-II procedure for assessing PDs is a two-stage
process. First, subjects complete a 120-item question-
naire with questions based on the criteria from the DSM-
IV. In the second stage, a semi-structured interview is
administered. Positive answers must be re-evaluated by
the interviewer in order to diagnose Axis-II PD. According
to the SCID-II protocol, we interviewed only those
subjects who achieved the cut-off (a specified number
of positive answers in a specific PD section) on the
questionnaire.
All SCID interviews were conducted by two psychologists
with graduate training in clinical psychology. To ensure
diagnostic reliability, 20 interviews (10 from each inter-
viewer) were videotaped and SCID rated by both psy-
chologists. A kappa coefficient was calculated to assess
inter-rater reliability. For Axis-I disorders, the kappa
coefficient was 0.89, indicating a good agreement
between the raters [25]. For Axis-II disorders, there was
agreement in 80% of the ratings, but it was not possible to
calculate the kappa coefficient due to the small number of
subjects diagnosed with an Axis-II disorder. In case of
missing inter-rater agreement, an experienced psychiatrist
was consulted to moderate.
Statistical Analysis
Variables are presented as means (M) and standard
deviations (SD) for continuous variables, and numbers
(N) and proportions (%) for categorical variables. We
compared our prevalence data for current (the previous
4 weeks) Axis-I and Axis-II disorders with those reported
in other general population-based studies (control
groups), using Fisher’s exact test [18,26]. The preva-
lence in the general population was adjusted by age and
sex compared with the population of the Rhein-Neckar
district. All statistical measures were calculated using
SPSS (Version 17.0; Chicago, IL, USA).
Non-Responder Analysis
Non-responder analysis was conducted by logistic
regression. A first non-responder analysis compared the
subjects who returned the questionnaire to the subjects
who did not respond. We found that older people and
women were more likely to participate. The second non-
responder analysis compared the subjects with CBP
who took part in the clinical examination to the subjects
who refused to participate. There were no differences in
terms of age or gender. However, differences were noted
in pain intensity over the previous 3 months and in social
class. High intensity pain was associated with a
decreased probability of participation, whereas subjects
from a higher social class were more likely to parti-
cipate. The following factors did not influence participa-
tion: marital status, education, occupational status,
receiving disability pension, self-reported impair-
ment, and the number of consultations over the last 3
months.
Results
The socio-demographic characteristics of subjects who
took part in the SCID study are shown in Table 1. The
mean age was 48 6 13.3 years, and 57% of the subjects
were female. A pain figure was used to categorize sub-
jects as to localized or widespread pain [27]. Approxi-
mately, 45.5% of the subjects administered the SCID
interview had chronic local pain (CLP) and 54.5% had
chronic widespread pain (CWP). The group of CWP
included one patient with diagnosis of fibromyalgia syn-
drome diagnosed according to American College of
Rheumatology (ACR) criteria [28]. Sixty percent of women
and 47% of men were diagnosed to have CWP (NS).
Table 2 shows the current prevalence and type of Axis-I
disorders in subjects with non-specific CBP, excluding
somatoform pain disorder. Of the subjects with non-
specific CBP, 39 subjects (35.5%) received at least
one Axis-I diagnosis. We observed no sex difference
(men = 36%, women = 35%, NS) and no differences com-
paring CLP with CWP (17% and 18%, respectively)
regarding prevalence of mental disorders. Anxiety disor-
ders (20.9%) and affective disorders (12.7%)
were the most frequently diagnosed, followed by
substance-related disorders (7.3%) and eating disorders
(5.5%).
The prevalence and the type of Axis-II disorders in
the non-specific CBP subjects are presented in Table 3.
Seventeen (15.5%) of the participants met the criteria for
at least one Axis-II PD. The most frequent diagnoses
Table 1 Socio-demographic variables of
non-specific chronic back pain patients
CBP Patients: N = 110 M (SD)
Age 48 6 (13.3)
N (%)
Gender
Female 63 (57)
Marital status
Single/divorced/widowed 32 (29)
Married 78 (71)
Education
<10 years 50 (45)
$10 years 54 (49)
Occupational status
Employed 67 (61)
Unemployed 12 (11)
School/apprenticeship 2 (2)
Occupational disability pension 4 (4)
Retirement pay 19 (17)
If subpoints (e.g. “employed,” “unemployed”) of a heading (e.g.,
“occupational situation”) do not sum up to 100%, this is due to
missing data.
CBP = chronic back pain.
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were obsessive-compulsive and avoidant PD (4.5% each),
followed by borderline PD (3.6%), paranoid PD (2.7%),
and narcissistic PD (0.9%). Thus, diagnoses in Cluster
C (anxious/inhibited) were the most prominent and
accounted for 9.1% of diagnoses.
In addition, we compared the prevalence of both Axis-I
and Axis-II disorders with their prevalence in other
population-based studies. Comparison of current (the
previous 4 weeks) Axis-I disorders between the study
participants and data from another population-based
study revealed a significant difference between the non-
specific CBP subjects in this study and individuals in the
general population [18]. Our CBP subjects showed a sig-
nificantly higher prevalence in each of the accumulated
categories (any Axis-I disorder: odds ratio [OR] 2.23,
P < 0.001; any anxiety disorder: OR 2.67, P < 0.001;
any mood disorder: OR 2.16, P < 0.05; any substance
related disorder: OR 2.64, P < 0.05; any eating disorder:
OR 29.04, P < 0.001). The comparison of Axis-II PDs in
our subjects and the data from the general population
showed no significant differences, other than in avoidant
PD in Cluster C (OR 4.24, P < 0.05) [26].
Discussion
To our knowledge, this is the first study of the prevalence
and the type of mental comorbidity in subjects suffering
from non-specific CBP who were recruited by a random-
ized representative population-based survey and admin-
istered the SCID. The main advantage of our approach
was the large number of individuals with non-specific
CBP that were drawn from the general population, rather
than from a specific clinical setting. The second strength
of this study was the simultaneous assessment of Axis-I
and Axis-II disorders. To the best of our knowledge, there
is no representative population-based study of patients
with CBP that assesses the prevalence and type of
Axis-II PDs using a validated instrument for DSM-IV. In
addition, the criterion for inclusion in the chronic pain
group was determined by a physical examination and
was not based solely on patients’ self-report, as is typical
of other studies.
In our sample, approximately one third (35.5%) of the
subjects had at least one current Axis-I disorder, excluding
somatoform pain disorders. This result is at the lower end
Table 2 Current prevalence of Axis-I disorders (DSM-IV) for non-specific CBP patients (N = 110)
DSM-IV Code N Prevalence (%)
At least one Axis-I disorder 39 35.5*
Affective disorders 14 12.7†
Major depression, single episode, mild 296.21 1 0.9
Major depression, single episode, moderate 296.22 1 0.9
Major depression, recurrent, mild 296.31 2 1.8
Major depression, recurrent, moderate 296.32 4 3.6
Dysthymia 300.4 3 2.7
Depressive disorder, not otherwise specified 311 2 1.8
Affective disorder due to a general medical condition 293.83 1 0.9
Anxiety disorder 23 20.9†
Panic disorder without agoraphobia 300.01 5 4.5
Panic disorder with agoraphobia 300.21 2 1.8
Agoraphobia without history of panic disorder 300.22 4 3.6
Social phobia 300.23 5 4.5
Specific phobia 300.29 7 6.4
Substance-related disorder 8 7.3†
Alcohol dependence 303.90 3 2.7
Multiple substance dependence 304.80 1 0.9
Alcohol abuse 305.00 4 3.6
Eating disorder 6 5.5†
Anorexia nervosa 307.1 2 1.8
Eating disorders, not otherwise specified 307.5 2 1.8
Bulimia nervosa 307.51 2 1.8
Acute stress disorder 308.3 1 0.9
Adjustment disorders 3 2.7
— With depressive mood 309.20 2 1.8
— With mixed anxiety and depressed mood 309.28 1 0.9
* Due to multiple diagnoses in some CBP patients, the sum for the prevalence of the different disorder-groups (e.g. “Affective
Disorders”, “Anxiety Disorders”, “Eating Disorders”) is higher than the prevalence for co-morbid Axis-I disorder (“At least one Axis-I
disorder”). † Deviations between the sum of the single diagnoses (e.g., “Anorexia Nervosa,” “Bulimia Nervosa”) and the proportion
of the disorder group (“Eating Disorders”) are a result of rounding.
CBP = chronic back pain; DSM-IV = Diagnostic and Statistical Manual of Mental Disorders, IV.
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of the previously reported range of mental comorbidity in
subjects with back pain [12–14,17]. However, this preva-
lence is still significantly elevated compared with the
general population. The prevalence of Axis-II PDs in this
study was 15.5%. Compared with clinical samples of
patients with back pain, this prevalence is rather low and
similar to the total prevalence of mental disorders in the
general population.
Other studies are in agreement with our findings of a
significantly higher, although moderate, prevalence of
mental comorbidity in patients with CBP (31%–38%)
[11,21,29,30]. A population-based case-control study
found that only 16.9% of individuals with CWP were
estimated to have a psychiatric diagnosis [31]. However,
this study used a non-representative population and
inadequate screening methods. To summarize, the
studies in the literature recruited patients from a clinical
setting, did not apply an international standardized
assessment instrument for the evaluation of mental disor-
ders or used another defined pain condition.
In our population, anxiety disorders were the most
common category of Axis-I mental disorders (20.9%), fol-
lowed by affective disorders (12.7%), substance-related
disorders (7.3%), and eating disorders (5.5%). Of Axis-II
disorders, PDs of Cluster C (anxious-avoidant) were the
most frequent (9.1%). When the psychopathological
aspects of both Axes are considered together, a consistent
tendency toward vulnerability to anxiety, fear and avoid-
ance were observed among our subjects, as reported
elsewhere [32]. Sensitivity toward anxiety can be viewed as
a precursor to pain-related fear or depression; avoidance
behavior or disability is thought to be a response to expe-
riencing pain [33–38]. Furthermore, avoidance may con-
tribute to the maintenance or exacerbation of chronic pain
and produce a number of additional negative physical and
psychological symptoms. Fearful people are more con-
scious of possible threatening signals and are therefore less
able to shift their attention away from pain-related informa-
tion [37]. Additional longitudinal studies are needed to
better understand the role of anxiety in chronic pain.
In our subjects, the prevalence of affective disorders
(12.7%) was greater than that of the general population.
The observation that affective disorders are the most fre-
quent mental comorbidity in patients suffering from pain
has been reported by others [12,15]. In our sample,
however, anxiety disorders were the most prevalent, which
is in agreement with data from the general population [18].
This might be due to our population-based setting, as
confirmed by other recent population-based studies
[19–21]. It can be hypothesized that in the medical system,
depressed patients tend to be identified more easily than
patients with anxiety disorders, perhaps because patients
with depression are more likely to seek help than patients
with anxiety disorders. Between one third and one half of
patients with depression seek help, whereas a lower
number of patients with anxiety disorders seek help
[39–42]. Therefore, clinicians should consider screening for
affective and anxiety disorders in patients with CBP. The
rehabilitation of patients with chronic pain may be compro-
mised if concurrent psychiatric disorders are not recog-
nized and adequately treated [43,44].
In our subjects, the prevalence of substance-related dis-
orders was low (7.3%). This result differs from Anglo-
American studies of patients with CBP, where reported
ranges of prevalence vary from 19% to 23% [12,45]. One
explanation for this difference may be cultural differences
in perceiving and/or reporting substance-related disor-
ders. This conclusion is supported by comparably small
rates in the comparison group [18].
The observed prevalence of eating disorders in our sub-
jects (5.5%) is high compared with other studies of CBP
patients as well as to the general population. This is sur-
prising, considering that psychophysiological studies
show an elevated pain threshold and a decreased sensi-
tivity to painful stimuli in patients diagnosed with either
bulimia or anorexia nervosa [46–48]. On the other hand, it
is known that obesity, which is often found in atypical
eating disorders, is a risk factor for developing CBP [49]. In
addition, osteoporosis (which is common in anorexia) is
associated with an increased risk of symptoms of pain
[50,51]. However, our findings should be interpreted care-
fully due to the small sample size.
The prevalence of PDs in our study are remarkably low in
comparison to a previous study [12]. It could be con-
Table 3 Prevalence of Axis-II disorders (DSM-IV)
for non-specific CBP patients (N = 110)
DSM-IV
Code N
Prevalence
(%)
At least one Axis-II disorder 17 15.5*
Cluster A (odd/eccentric) 3 2.7
Paranoid PD 301.00 3 2.7
Cluster B (dramatic/erratic) 5 4.5
Borderline PD 301.83 4 3.6
Narcissistic PD 301.81 1 0.9
Cluster C (anxious/inhibited) 10 9.1†
Obsessive-compulsive PD 301.4 5 4.5
Avoidant PD 301.82 5 4.5
Negativistic (passive-
aggressive) PD‡
1 0.9
* Due to multiple diagnoses in some CBP patients, the sum
of the prevalence of the different Clusters is higher than the
prevalence for comorbid Axis-II disorder (“At least one Axis-II
disorder”).
† Deviations between the sum of the single diagnoses (e.g.,
“obsessive-compulsive PD,” “avoidant PD”) and the proportion
of the Clusters (e.g., “Cluster C”) are a result of rounding.
‡ This is not yet an official category of Axis-II disorders in the
DSM-IV but it is listed in DSM-IV Appendix B as a suggestion
for a new category.
CBP = chronic back pain; PD = Personality Disorder; DSM-IV =
Diagnostic and Statistical Manual of Mental Disorders, IV.
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cluded that the relatively moderate prevalence of PD
observed in our study may be attributed to our non-
selective population-based sample that was not con-
founded by a high rate of help-seeking behavior. It would
be interesting to compare further samples of pain subjects
with respect to PD.
Our study has several limitations. The overall rate of return
of our postal survey was 60.1% after two reminders.
However, this is comparable with other studies [23,52–
54]. Non-responder analyses revealed only slight differ-
ences between participants and non-participants. Return
of initial pain assessment questionnaire was associated
with older age and female sex. In general, women are
more likely to suffer from mental disorders than men [18].
Thus, there might be an overestimation of mental comor-
bidity in our study. However, in our study, women were not
more likely to have mental comorbidity than man. In regard
to age, most disorders develop early in life [18]; thus,
influence of a higher proportion of older aged participants
might be attenuated.
The second dropdown from the identified 188 patients
with non-specific CBP to the 110 patients that completed
SCID procedure was addressed by second non-
responder analyses. Analyses revealed that subjects from
a higher social class and subjects with less pain intensity
were more likely to participate in the physical examination
and SCID procedure. Lower socioeconomic status is
usually associated with greater risk for mental disorders
[18]. The higher response rate of patients with higher
socioeconomic status might also explain the low rate of
Axis-II disorders because especially PDs are concentrated
in lower socioeconomic groups [55]. Moreover, it might be
that especially the group with high pain intensity has great-
est psychiatric comorbidity, thus underestimating preva-
lence of mental comorbidity in our CBP sample. These
findings offer the possibility of underestimating prevalence.
We were also surprised not to capture generalized anxiety
disorder (GAD) with the SCID. Perhaps it might be that
patients with GAD have belonged to the non-responders
and were less likely to participate in a voluntarily study on
CBP that might not target at their GAD symptomatology.
The observed influence of age, sex, and socioeconomic
class on participation in research is well known [52,56,57].
Moreover, studies have shown that persons who respond
to surveys on CBP or mental disorders might be slightly
more likely to suffer from the complain in focus [52,58,59].
Thus, a low response rate offers potential to slightly over-
estimate prevalence. Strictly speaking, results can only be
generalized for groups containing more women and older
aged people with higher socioeconomic status. Therefore,
we advocate studies targeting especially at lower socio-
economic groups. Moreover, inclusion of a higher number
of subjects would be desirable.
However, other studies have shown that non-responders
do not, or only slightly, affect prevalence data for pain or
mental variables [52,58–60]. A recent study shows that
this is also the case in the event of attrition [61]. Further-
more, the response rate to the SCID interview was high.
Therefore, we assume that the moderately higher preva-
lence of Axis-I disorders that we observed is not a matter
of sampling bias.
It should also be mentioned that the differences in preva-
lence between our sample and other populations might
have been affected by unequal methods of diagnostic
assessment. We therefore based our comparisons on
groups of disorders rather than on a single diagnosis, to
overcome differences in assessment method. We decided
to use the SCID method because it is the most valid and
widely used assessment standard today. For optimal
comparison and to improve explanatory power, future
studies should implement a case control design with equal
assessment methods.
Conclusion
The high prevalence of mental comorbidity in subjects
with non-specific CBP emphasizes the need for an
increased awareness of the possibility of mental disorders
in patients with CBP. In particular, the observed consis-
tency of anxiety, fear, and avoidance points to the impor-
tance of being aware of anxiety disorders, in addition to
the affective disorders that are the most frequently self-
reported disorder, in patients with CBP. The recognition of
anxiety, fear, and avoidance may be well established in
research and in specialized pain centers. However, our
population-based setting captures also patients with low
pain intensity and probably low help-seeking behavior.
These patients suffer from mental comorbidity, too. Not
treating that condition might burden patients and possibly
maintain or exacerbate CBP. Therefore, we recommend
that a standardized screening for and assessment of
mental disorders should be implemented in conjunction
with the initial pain assessment at regular intervals. This
should also be done in primary care and not only in
research or specialized pain centers. This procedure
might help to eliminate a high number of untreated
patients who may be reluctant to seek help in overcoming
pain due to their anxiety disorder.
Acknowledgments
This study was supported by a research grant from the
Federal Ministry of Education and Research (BMBF) as
part of the GBPRN, Project 01EM0112.
References
1 Bassols A, Bosch F, Campillo M, Canellas M, Banos
JE. An epidemiological comparison of pain complaints
in the general population of Catalonia (Spain). Pain
1999;83(1):9–16.
2 Chrubasik S, Junck H, Zappe HA, Stutzke O. A survey
on pain complaints and health care utilization in a
German population sample. Eur J Anaesthesiol
1998;15(4):397–408.
1237
Mental Disorders in Non-Specific Chronic Back Pain
3 Negrini S, Fusco C, Atanasio S, Romano M, Zaina F.
Low back pain: State of art. Eur J Pain Suppl
2008;2(1):52–6.
4 Harkness EF, Macfarlane GJ, Silman AJ, McBeth J. Is
musculoskeletal pain more common now than 40
years ago?: Two population-based cross-sectional
studies. Rheumatology 2005;44(7):890–5.
5 Hasselstrom J, Liu-Palmgren J, Rasjo-Wraak G.
Prevalence of pain in general practice. Eur J Pain
2002;6(5):375–85.
6 Walker BF. The prevalence of low back pain: A sys-
tematic review of the literature from 1966 to 1998.
J Spinal Disord 2000;13(3):205–17.
7 O’Brien E, Staud R, Hassinger A, et al. Patient-
centered perspective on treatment outcomes in
chronic pain. Pain Med 2010;11(1):6–15.
8 Robinson M, Brown J, George S, et al. Multidimen-
sional success criteria and expectations for treatment
of chronic pain: The patient perspective. Pain Med
2005;6(5):336–45.
9 Croft P, Papageorgiou A, Ferry S, et al. Psychological
distress and low back pain. Evidence from a pro-
spective study in the general population. Spine
1995;20(10):2731–7.
10 Macfarlane GJ. Looking back: Developments in our
understanding of the occurrence, aetiology and prog-
nosis of chronic pain 1954–2004. Rheumatology
2005;44(suppl 4):iv23–6.
11 Härter M, Reuter K, Weisser B, et al. A descriptive
study of psychiatric disorders and psychosocial
burden in rehabilitation patients with musculoskeletal
diseases. Arch Phys Med Rehabil 2002;83(4):461–8.
12 Polatin P, Kinney RK, Gatchel RJ, Lillo E, Mayer TG.
Psychiatric illness and chronic low-back pain. The
mind and the spine—Which goes first? Spine
1993;18(1):66–71.
13 Atkinson JH, Slater MA, Patterson TL, Grant I, Garfin
SR. Prevalence, onset, and risk of psychiatric disor-
ders in men with chronic low back pain: A controlled
study. Pain 1991;45(2):111–21.
14 Dersh J, Gatchel RJ, Polatin P, Mayer T. Prevalence
of psychiatric disorders in patients with chronic
work-related musculoskeletal pain disability. J Occup
Environ Med 2002;44(5):459–68.
15 Kinney R, Gatchel R, Polatin P, Fogarty W. Prevalence
of psychopathology in acute and chronic low back
pain patients. J Occup Rehabil 1993;3(2):95–103.
16 Regier DA, Boyd JH, Burke JD, et al. One-month
prevalence of mental disorders in the United States.
Based on five Epidemiologic Catchment Area sites.
Arch Gen Psychiatry 1988;45(11):977–86.
17 Katon W, Egan K, Miller D. Chronic pain: Lifetime
psychiatric diagnoses and family history. Am J
Psychiatry 1985;142(10):1156–60.
18 Jacobi F, Wittchen HU, Holting C, et al. Prevalence,
co-morbidity and correlates of mental disorders in the
general population: Results from the German Health
Interview and Examination Survey (GHS). Psychol Med
2004;34(4):597–611.
19 McWilliams L, Cox B, Enns M. Mood and anxiety
disorders associated with chronic pain: An exa-
mination in a nationally representative sample. Pain
2003;106:127–33.
20 Stang P, Brandenburg N, Lane M, et al. Mental and
physical comorbid conditions and days in role among
persons with arthritis. Psychosom Med 2006;68(1):
152–8.
21 von Korff M, Crane P, Lane M, et al. Chronic spinal
pain and physical-mental comorbidity in the United
States: Results from the national comorbidity survey
replication. Pain 2005;113:331–9.
22 Kohlmann T. Muskuloskelettale Schmerzen in der
Bevölkerung [Musculoskeletal pain in the population].
Schmerz 2003;17(6):405–11.
23 Schmidt C, Raspe H, Pfingsten M, et al. Back pain in
the German adult population: Prevalence, severity,
and sociodemographic correlates in a multiregional
survey. Spine 2007;32(18):2005–11.
24 Wittchen H-U, Zaudig M, Fydrich T. SKID-I U. II: Struk-
turiertes Klinisches Interview Für DSM-IV. Achse I:
Psychische Störungen [SCID-I and -II: Structured
Clinical Interview for DSM-IV. Axis-I: Mental Disorders].
Göttingen: Hogrefe Verlag für Psychologie; 1997.
25 Spitzer R, First M, Gibbon M, Williams J, Caban D.
What is the reliability of the SCID? Official web site
for the Structured Clinical Interview for DSM dis-
orders SCID. 2009. Available at: http://cpmcnet.
columbia.edu/dept/scid/psychometric/scidII_
reliability.html (accessed February 16, 2011).
26 Maier W, Lichtermann D, Klingler T, Heun R,
Hallmayer J. Prevalences of personality disorders
(DSM-III-R) in the community. J Pers Disord 1992;6(3):
187–96.
27 Margolis RB, Tait RC, Krause SJ. A rating system for
use with patient pain drawings. Pain 1986;24(1):57–
65.
1238
Gerhardt et al.
28 Wolfe F, Smythe HA, Yunus MB, et al. The American
College of Rheumatology 1990 criteria for the classi-
fication of fibromyalgia. Arthritis Rheum 1990;33(2):
160–72.
29 Joukamaa M. Low back pain and psychological
factors. A social psychiatric study of the population of
working age. Psychother Psychosom 1991;55(2–
4):186–90.
30 Mayr M, Hogler S, Ghedina W, Berek K. Low
back pain and psychiatric disorders. Lancet
2003;361(9356):531.
31 Benjamin S, Morris S, McBeth J, Macfarlane G, Silman
A. The association between chronic widespread pain
and mental disorder: A population-based study.
Arthritis Rheum 2000;43(3):561–7.
32 Malmgren-Olsson E, Bergdahl J. Temperament and
character personality dimensions in patients with
nonspecific musculoskeletal disorders. Clin J Pain
2006;22(7):625–31.
33 Alschuler K, Theisen-Goodvich M, Haig A, Geisser M.
A comparison of the relationship between depression,
perceived disability, and physical performance in
persons with chronic pain. Eur J Pain 2007;12(6):757–
64.
34 Keogh E, McCracken L, Eccleston C. Gender moder-
ates the association between depression and disability
in chronic pain patients. Eur J Pain 2006;10(5):413–
22.
35 Leeuw M, Houben R, Severeijns R, et al. Pain-related
fear in low back pain: A prospective study in the
general population. Eur J Pain 2007;11(3):256–66.
36 Murphy D, Lindsay S, Williams AC. Chronic low back
pain: Predictions of pain and relationship to anxiety
and avoidance. Behav Res Ther 1997;35(3):231–8.
37 Vlaeyen JW, Linton SJ. Fear-avoidance and its con-
sequences in chronic musculoskeletal pain: A state of
the art. Pain 2000;85(3):317–32.
38 Vowles KE, Zvolensky MJ, Gross RT, Sperry JA. Pain-
related anxiety in the prediction of chronic low-back
pain distress. J Behav Med 2004;27(1):77–89.
39 Essau CA, Conradt J, Petermann F. Frequency,
comorbidity, and psychosocial impairment of anxiety
disorders in German adolescents. J Anxiety Disord
2000;14(3):263–79.
40 Henderson JG, Pollard CA, Jacobi KA, Merkel WT.
Help-seeking patterns of community residents with
depressive symptoms. J Affect Disord 1992;26(3):
157–62.
41 Meller I, Fichter M, Weyerer S, Witzke W. The use of
psychiatric facilities by depressives: Results of the
Upper Bavarian Study. Acta Psychiatr Scand
1989;79(1):27–31.
42 Olfson M, Guardino M, Struening E, et al. Barriers to
the treatment of social anxiety. Am J Psychiatry
2000;157(4):521–7.
43 Dersh J, Mayer T, Gatchel R, et al. Psychiatric comor-
bidity in chronic disabling occupational spinal disor-
ders has minimal impact on functional restoration
socioeconomic outcomes. Spine 2007;32(17):1917–
25.
44 Gatchel R. Psychological disorders and chronic pain:
Cause and effect relationships. In: Gatchel R, Turk D,
eds. Psychological Approaches to Pain Management:
A Practioner’s Handbook. New York: Guilford Publica-
tions; 1996:33–54.
45 Brown RL, Patterson JJ, Rounds LA, Papasouliotis O.
Substance abuse among patients with chronic back
pain. J Fam Pract 1996;43(2):152–60.
46 de Zwaan M, Biener D, Schneider C, Stacher G. Rela-
tionship between thresholds to thermally and to
mechanically induced pain in patients with eating
disorders and healthy subjects. Pain 1996;
67(2–3):511–2.
47 Lautenbacher S, Pauls AM, Strian F, Pirke KM, Krieg
JC. Pain perception in patients with eating disorders.
Psychosom Med 1990;52(6):673–82.
48 Papezova H, Yamamotova A, Uher R. Elevated
pain threshold in eating disorders: Physiological and
psychological factors. J Psychiatr Res 2005;39(4):
431–8.
49 Marcus DA. Obesity and the impact of chronic pain.
Clin J Pain 2004;20(3):186–91.
50 Gaber TA, McGlashan KA, Love S, Jenner JR, Crisp
AJ. Bone density in chronic low back pain: A pilot
study. Clin Rehabil 2002;16(8):867–70.
51 Johnson JG, Cohen P, Kasen S, Brook JS. Eating
disorders during adolescence and the risk for physical
and mental disorders during early adulthood. Arch
Gen Psychiatry 2002;59(6):545–52.
52 Papageorgiou AC, Croft PR, Ferry S, Jayson MI,
Silman AJ. Estimating the prevalence of low back pain
in the general population. Evidence from the South
Manchester Back Pain Survey. Spine 1995;20(17):
1889–94.
53 Asch DA, Jedrziewski MK, Christakis NA. Response
rates to mail surveys published in medical journals.
J Clin Epidemiol 1997;50(10):1129–36.
1239
Mental Disorders in Non-Specific Chronic Back Pain
54 Cook JV, Dickinson HO, Eccles MP. Response rates
in postal surveys of healthcare professionals between
1996 and 2005: An observational study. BMC Health
Serv Res 2009;9:160.
55 Torgersen S, Kringlen E, Cramer V. The prevalence of
personality disorders in a community sample. Arch
Gen Psychiatry 2001;58:590–6.
56 Fejer R, Hartvigsen J, Kyvik KO, et al. The Funen Neck
and Chest Pain Study: Analysing non-response bias
by using national vital statistic data. Eur J Epidemiol
2006;21:171–80.
57 Hüppe A, Müller K, Raspe H. Is the occurrence of
back pain in Germany decreasing? Two regional
postal services a decade apart. Eur J Public Health
2006;17(3):318–22.
58 Lundberg I, Damström Thakker K, Hällström T, Forsell
Y. Determinants of non-participation, and the effects
of non-participation on potential cause-effect relation-
ships, on the part study of mental disorders. Soc
Psychiatry Psychiatr Epidemiol 2005;40:475–83.
59 Bijl RV, van Zessen G, Ravelli A, de Rijk C, Langen-
doen Y. The Netherlands Mental Health Survey and
Incidence Study (NEMESIS): Objectives and design.
Soc Psychiatry Psychiatr Epidemiol 1998;33:581–6.
60 Moum T. Is subjective well-being a predictor of non-
respondence in broad population surveys? Soc Indic
Res 1994;32(1):1–20.
61 Schmidt CO, Raspe H, Pfingsten M, et al. Does attri-
tion bias longitudinal population-based studies on
back pain? Eur J Pain 2011;15:84–91.
1240
Gerhardt et al.
Quantitative Sensory Testing Profiles in Chronic
Back Pain Are Distinct From Those in Fibromyalgia
Klaus Blumenstiel, MD,*w Andreas Gerhardt, MA,* Roman Rolke, MD,zy Christiane Bieber, MD,*
Jonas Tesarz, MD,* Hans-Christoph Friederich, MD,* Wolfgang Eich, MD, PhD,*
and Rolf-Detlef Treede, MD, PhDJ
Objectives: Alterations in the central nervous system leading to
higher pain sensitivity have been shown in both chronic back pain
(CBP) and fibromyalgia syndrome (FMS). The aim of this study
was to disclose commonalities and differences in the pathophysio-
logy of FMS and CBP.
Methods: We used the quantitative sensory testing protocol of the
German Research Network on Neuropathic Pain to obtain
comprehensive profiles of somatosensory functions. The protocol
comprised thermal and mechanical detection and pain thresholds,
vibration thresholds, and pain sensitivity to sharp and blunt
mechanical stimuli. We studied 21 FMS patients (mean pain
duration: 13.4 y), 23 CBP subjects (mean pain duration: 15.9 y),
and 20 healthy controls (HCs). Each participant received the test
battery on the back and on the dorsal hand (pain-free control site).
Results: On the back, FMS patients showed increased thermal and
mechanical pain sensitivity compared with HCs and CBP
participants. On the hand dorsum, FMS patients showed higher
mechanical pain sensitivity compared with CBP participants and
HCs and higher cold pain sensitivity compared with HCs. CBP
participants showed increased pressure pain sensitivity and lower
vibration sensitivity on the back, but no significant differences on
the hand dorsum compared with HCs.
Discussion: FMS patients showed increased sensitivity for different
pain modalities at all measured body areas, suggesting central
disinhibition as a potential mechanism. CBP participants in
contrast, showed localized alterations within the affected segment
possibly due to peripheral sensitization.
Key Words: fibromyalgia syndrome (FMS), chronic back pain
(CBP), quantitative sensory testing (QST)
(Clin J Pain 2011;27:682–690)
Fibromyalgia syndrome (FMS) and chronic back pain(CBP) are common, an increasing cause of consultations
in primary care, and of enormous socioeconomic rele-
vance.1,2 Therapeutic interventions are often unspecific and
of minor success,3,4 probably because of the fact that their
etiologies and pathogeneses are still widely unknown.
Despite much research, the pathogenesis of FMS is
still a matter of debate. One of the most promising
approaches addresses the role of the (central) nervous
system (CNS). A series of techniques have been applied
to detect abnormalities in the CNS, such as functional
neuroimaging, electrophysiological techniques, laser-
evoked potentials, investigation of spinal fluid, and, in
particular, quantitative sensory testing (QST).5 QST is a
method that is used to assess the somatosensory function. A
comprehensive QST protocol allows to determine pain and
detection thresholds and to distinguish local versus general-
ized and peripheral versus central nervous mechanisms. To
date, QST studies in FMS have shown decreased mech-
anical/pressure and thermal pain thresholds,6–9 temporal
summation of pain (“wind-up”) reflecting an increased
excitability of spinal cord neurons,10 and signs of central
hypersensitivity.11 Other studies suggest a reduced habitua-
tion to pain12 and central sensitization13,14 as mechanisms
involved.
QST aberrations including signs for abnormal central
nervous pathways have also been found in nonspecific CBP,
the most common type of all CBPs.15 Studies reported low
pain thresholds and pain tolerance values.16 A study by
Giesecke et al17 revealed hyperalgesia in FMS and CBP
patients in comparison with healthy controls (HCs) when
experimental pain was applied to a neutral site (thumbnail).
Moreover, patients with FMS and CBP showed similar
activation in pain-related cortical areas in functional
magnetic resonance imaging, which was different from that
in HCs. Baraniuk et al18 studied opioid neurotransmitters
in the cerebrospinal fluid and found that Met-enkephalin-
Arg6-Phe7 was greater in both FMS and CBP patients than
in HCs. In addition, FMS patients often report that their
disease started with simple back pain19,20 and thus CBP
may be a pre-stage to FMS.21
It is the main hypothesis of a mechanism-based
diagnosis in chronic pain syndromes that defined symptoms
and signs reflect possible underlying neurobiological pain
mechanisms.22,23 Although in the case of a central
disinhibition all types of thermal and mechanical pain
thresholds may be generally decreased with an increased
response to suprathreshold stimuli, thermal and mechanical
detection and pain thresholds are increased in the presence
of deafferentiation due to axonal damage. Moreover,
localized pin-prick hyperalgesia and/or dynamic mechanicalCopyright r 2011 by Lippincott Williams & Wilkins
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allodynia may point to a central sensitization of the
nociceptive system, whereas localized heat and pressure
hyperalgesia are cardinal signs of a peripheral sensitization.
Hence, we addressed the following questions in the present
study:
(1) Are there distinct sensory profiles in FMS and CBP?
(2) If so, do clinical signs conclusively reflect possible
underlying neurobiology?
(3) Do FMS and CBP share the same neurobiological
mechanisms as indirectly reflected by QST?
MATERIALS AND METHODS
Participants
In the present study, 21 patients with a diagnosis
of FMS, 23 participants with CBP, and 20 HCs were
included. Inclusion criteria were female sex and being free
of diseases affecting sensory processes (for sociodemo-
graphic data, see Table 1). Study participants were screened
(physical examination, blood tests, past medical history,
and, if indicated, further technical investigations such as
x-ray or magnetic resonance imaging) to rule out diseases
affecting sensory processes. Patients were also excluded if
they reported pain at the hand dorsum, as this area was
destined to be the control site.
FMS patients who fulfilled the diagnostic American
College of Rheumatology criteria24 were recruited from an
outpatient clinic of the Medical University Hospital of
Heidelberg. The CBP sample was drawn from participants
who had a sample in an epidemiological study on CBP
(Generalization of Pain: A Prospective Population-based
Survey with Clinical Examination as part of the German
Back Pain Research Network, supported by the Federal
Ministry of Education and Research). A representative
sample of 4000 inhabitants in the south-west of Germany
was approached by mail and they were asked whether they
had CBP. CBP was defined as the presence of back pain for
at least 45 days within the last 3 months. A total of 2408
individuals responded to the mail survey. Of them, 427
fulfilled the criteria of CBP and were invited to a clinical
investigation. Finally, 303 individuals participated in the
study. Participants were questioned about the existence
of comorbidity (explicitly neuropathy, diabetes, relevant
alcohol consumption, infections, inflammatory diseases,
disc hernia, past severe injuries) and they received a
physical examination (general, rheumatological, neurologi-
cal). In case of signs for serious pathological findings (eg,
ischialgia or severe injuries such as whiplash), participants
were excluded, and a further investigation was advised. Of
the 303 participating individuals, 20 repored specific back
pain (5 had Bechterew disease, 3 rheumatoid arthritis
affecting the spine, 1 polymyalgia rheumatica, 3 tumor/
metastases, 1 fracture of the vertebral body, 1 spondylo-
lysis, and 6 disc hernia). The remaining 283 participants
represented a nonhomogeneous group of nonspecific CBP
according to the distribution in the general population. Of
them, 23 female participants with nonspecific back pain
were included in the present QST investigation consecu-
tively. Participants were advised not to take pain medica-
tion 24 hours before investigation. HCs were recruited per
advertisement. All participants were white.
The present study has been approved by the Ethics
Research Committee of the Faculty of Medicine, University
of Heidelberg. Participants gave written informed consent.
They received an allowance of 10 Euros (about 12 dollars).
The study was carried out in compliance with the
Declaration of Helsinki.
Disability
Disability levels were measured using the FFbH
(Hannover Functional Ability Questionnaire for measuring
pain-related disability). It consists of 12 self-administered
items that especially focus on daily activities restricted by
musculoskeletal disorders (eg, “Can you wash your hair in
a washbasin”). The response format is in 3 stages (“yes,”
“yes with trouble,” “no or with the help of another
person”). The answers were transformed to a functional
ability score ranging from 0% to 100% (80% to 100%=no
functional disability, about 70%=moderate disability,
<60=relevant disability). Data from different studies
indicate that the FFbH meets relevant psychometric criteria
and is sensitive to change.25
QST Protocol
The somatosensory function was assessed using the
comprehensive QST protocol that was developed as part of
the German Research Network on Neuropathic Pain
(DFNS).26 It covers all relevant aspects of the somatosen-
sory system, including large and small fiber function, and
signs of central sensitization (dynamic tactile allodynia,
punctate mechanical hyperalgesia). In this manner, detailed
profiles of somatosensory function for the tested body areas
are obtained.
Test sites were over paraspinal muscles and on the
dorsum of the hand. Patients with FMS and CBP were
tested on the most painful area in the back and on the hand
dorsum of the same side of the body as a pain-free control
site. The most painful area was determined on the basis of
the patient’s report during the office visit about present
ongoing pain. Nine FMS patients were tested on the left,
whereas 12 were tested on the right side of the body.
Among CBP patients, 9 were tested on the left and 14 on
the right side of the body, which was not significantly
different from the FMS group (w2>0.05). In CBP, all
paraspinal test sites were in lumbar segments. For FMS, 16
test sites were in cervical and 5 were in lumbar segments.
We had previously found that pressure pain thresholds
(PPTs) are quite uniform across different muscles.27 Pain-
free controls were tested on the hand dorsum and in
cervical segments (over the trapezius muscle) of both sides
of the body. All tests were first conducted over an area that
was not tested later during the QST session.
Thermal Detection and Thermal Pain Thresholds
The tests for thermal detection, thermal pain thresh-
olds, and paradoxical heat sensations (PHS) were con-
ducted using a TSA 2001-II (MEDOC, Israel) thermal
sensory testing device.28 All thresholds were obtained with
ramped stimuli (11C/s, 321C baseline, 01C and 501C cutoffs,
8 cm2 thermode), which were terminated when participants
pressed a button. The mean of 3 consecutive measurements
was calculated. Thermal sensory limen, a test with
alternating warming and cooling ramps, was used only as
a provocative test to induce PHS.
Mechanical Detection Threshold
Mechanical detection threshold (MDT) was measured
with a standardized set of modified von Frey filaments
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(Optihair2-Set, Marstock Nervetest, Germany) that exert
forces between 0.25 and 256mN.29 The contact area was of
uniform size and shape (round, 0.5mm diameter). The
threshold was the geometric mean of 5 series of ascending
and descending stimulus intensities.
Mechanical Pain Threshold
Mechanical pain threshold (MPT) was measured using
a set of weighted pinprick stimulators with a flat contact
area of 0.25mm diameter that exert forces between 8 and
512mN.30 Again using the method of limits, the threshold
was the geometric mean of 5 series of ascending and
descending stimulus intensities.
Mechanical Pain Sensitivity Including Dynamic
Mechanical Allodynia
Mechanical pain sensitivity (MPS) was tested using the
same weighted pinprick stimuli as that for MPT. To obtain
stimulus response function, these 7 pin pricks were applied
in balanced order, 5 times each. The participant was asked
to rate each stimulus for pain on a 0 to 100 numerical rating
scale (0 indicating “no pain,” and 100 indicating “most
intense pain imaginable”). The geometric mean of the 35
pain ratings was the final value for MPS. Stimulus response
functions for dynamic mechanical allodynia (DMA) were
determined using a set of 3 light tactile stimulators.30,31
They were intermingled with the pin-prick stimuli in
balanced order and participants were asked to give a rating
on the same numeric rating scale.
Wind-up Ratio
The ratings of single pin-prick stimulation were
compared with those of a series of 10 repeated pin-prick
stimuli of the same force (256mN) over the same area.
Wind-up ratio (WUR) was calculated by dividing the mean
ratings of series by the mean pain ratings of single stimuli.
Vibration Detection Threshold
Vibration detection threshold (VDT) was determined
with a Rydel-Seiffer tuning fork (64Hz, 8/8 scale), which
was placed 3 times over a bony prominence of the tested
body area. Participants indicated the disappearance of
vibratory sensations.
PPT
The PPT was measured using an Algometer (Somedic,
Sweden) with a probe diameter of 1.1 cm that exerts
pressure up to 2000 kPa. The PPT is determined by 3
ramped stimuli, each applied with a slope of 50 kPa/s.
Statistical Analysis
Most QST parameters cold detection threshold
(CDT), warmth detection threshold (WDT), thermal
sensory limen, PPT, MPT, MPS, DMA, WUR, and
MDT) are log-normally distributed and were therefore
log-transformed.26 The QST values of each tested body
area of the control group were averaged across both sides of
the body. To compare QST measures at both sides (most
painful area in the back and hand dorsum) between the 3
groups, analyses of covariance (ANCOVA) were calculated
for each modality, followed by Fisher least significant
difference tests (Tables 2 and 3). QST values were entered as
dependent variables and pain group (FMS, CBP, and HC)
was entered as the independent variable. As the 3 groups
significantly differed in age (P<0.001), age was included as
a covariate, because QST parameters are age dependent.32
To compare the 2 test sites within each patient group
(localized vs. generalized QST aberrations), all QST
measures were standardized by z-transformation referring
to the group of pain-free controls (QST profiles in Figs. 1,
2). This is carried out through z-transformation of all QST
measures of the FMS and CBP groups, referring to the
TABLE 1. Sociodemographic Variables
Fibromyalgia Chronic Back Pain Pain-free Healthy Controls
N 21 23 20
Age, mean (SD) 50.6 (9.5) 43.4 (8.6) 38.3 (7.6)
Marital status, N (%)
Unmarried 9 (45) 3 (13) 12 (58)
Married 9 (45) 14 (61) 5 (24)
Divorced/separated 2 (15) 6 (26) 1 (5)
Widowed 0 0 2 (9)
Not specified 0 0 2 (9)
Education, N (%)
<10 y of education 13 (64) 9 (39) 1 (5)
Z10 y of education 6 (29) 14 (61) 19 (95)
Not specified 2 (9) 0 0
Occupational situation, N (%)
Full-time working 5 (24) 8 (35) 10 (50)
Part-time working 5 (24) 6 (26) 8 (40)
Not working/homemaker 1 (5) 8 (35) 2 (10)
Retired 6 (26) 0 0
Unemployed 2 (9) 0 0
Not specified 2 (9) 1 (5) 0
Pain intensity before QST, mean (SD) 5.8 (1.8) 3.0 (2.2) 0
Pain duration in years, mean (SD) 13.4 (10.4) 15.9 (11.5) 0
Painful tender points 15.2 (2.3) 4.7 (3.8) 0
FFbH (disability), % (SD) 60 (18) 70 (16)
Pain intensity before QST was assessed on a numeric rating scale 0 to 10. “0” indicating “no pain,” “10” indicating “worst pain imaginable.” Painful tender
points were identified by tenderness examination using ACR criteria. FFbH (Hannover Functional Ability Questionnaire): measures pain-related disability
(80% to 100%=no functional disability; about 70%=moderate disability; <60%=relevant disability).
Blumenstiel et al Clin J Pain  Volume 27, Number 8, October 2011
684 | www.clinicalpain.com r 2011 Lippincott Williams & Wilkins
mean and standard deviation of the pain-free control
group. Whenever log-transformed scores were calculated,
the log scores were used for z-standardization. The
representation of QST profiles as z-transformed data allows
the direct comparison between sensory tests that are
measured in different units (eg, 1C and mN) and the
comparison of test sites that have different ranges of normal
values. To compare standardized QST measures of the
most painful area in the back with standardized QST
measures of the hand dorsum, paired t tests were calculated
for both disease groups. Moreover, to compare QST
parameters of the hand and back in FMS and CBP patients
with that of HCs (Figs. 1 and 2), t tests were applied.
Sensory findings on the hand were also compared with the
published DFNS reference data,32 both by group compar-
ison and by counting the number of patients who were
outside the 95% confidence interval (CI); DFNS reference
data for the back are not yet available.
RESULTS
In FMS patients, the mean duration of pain was
13.4±10.4 years (mean±SD). The average duration of
TABLE 2. Analysis of Covariance, Mean Values, and Confidence Intervals for Quantitative Sensory Testing of the Most Painful Area in the
Back
ANCOVA Fibromyalgia Chronic Back Pain Pain-free Controls
F P Mean 95% CI Mean 95% CI Mean 95% CI
CDT D1C 0.650 0.526 1.55 1.13-2.10 1.72 1.31-2.25 1.37 1.02-1.85
WDT D1C 1.36 0.264 2.72 2.18-3.38 3.22 2.66-3.90 2.61 2.12-3.21
CPT 1C 5.70 <0.01 22.96w,J 18.46-27.47 13.97 10.05-17.90 12.89 8.59-17.20
HPT 1C 3.88 <0.05 41.60*,y 39.82-43.39 44.73 43.17-46.29 44.65 42.94-46.36
PPT kPa 7.15 <0.01 199z=0.001 161-244 239.3w 200-287 352 286-432
MPT mN 7.26 <0.01 21.38z=0.001J 14.52-31.48 45.71 32.89-63.68 61.94 42.36-90.57
MPS NRS100 9.73 <0.001 1.82
z,z 0.99-3.37 0.35 0.21-0.60 0.31 0.17-0.57
WUR 2.03 0.141 2.36 1.67-3.32 2.36 1.74-3.21 3.61 2.56-5.11
MDT mN 1.05 0.355 6.10 3.45-10.79 6.05 3.75-9.77 3.67 2.09-6.43
VDT /8 3.41 <0.05 7.10 6.72-7.47 6.69* 6.36-7.02 7.31 6.93-7.69
Values of CDT, WDT, PPT, MPT, MPS, WUR, and MDT were calculated by back transformation from the log-means.
*P<0.05 vs. controls.
wP<0.01 vs. controls.
zP<0.001 vs. controls.
Significant test results for fibromyalgia vs. chronic back pain are denoted.
yP<0.05.
JP<0.01.
zP<0.001, respectively.
CDT indicates cold detection threshold; CI, confidence interval; CPT, cold pain threshold; HPT, heat pain threshold; MDT, mechanical detection
threshold; MPS, mechanical pain sensitivity; MPT, mechanical pain threshold; PPT, pressure pain threshold; VDT, vibration detection threshold; WDT,
warmth detection threshold; WUR, wind-up ratio.
FIGURE 1. QST profiles in fibromyalgia syndrome. Circles: hand,
triangles: back. Filled symbols: significant versus healthy controls
(open symbols: n.s.; t test). *P<0.05, **P<0.01, ***P<0.001,
paired t test hand versus back. Parallel profiles between hand and
back indicate generalized sensory changes. CDT, cold detection
threshold; CPT, cold pain threshold; HPT, heat pain threshold;
MDT, mechanical detection threshold; MPS, mechanical pain
sensitivity; MPT, mechanical pain threshold; PPT, pressure pain
threshold; TSL, thermal sensory limen; VDT, vibration detection
threshold; WDT, warm detection threshold; WUR, wind-up ratio;
Values are mean±SEM.
FIGURE 2. QST profiles in chronic back pain. Circles: hand,
triangles: back. Filled symbols: significant versus healthy controls
(open symbols: n.s.; t tests). *P<0.05, ***P<0.001, paired t test
hand versus back. Significant differences indicate that sensory
changes are localized to the back. For abbreviations, see legend
to Figure 1. Values are mean±SEM.
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CBP was 15.9±11.5 years (mean±SD). FMS patients
rated pain intensity (directly before QST investigation)
higher on a numeric rating scale (0 to 10) compared with
CBP participants (mean±SD 5.8±1.8 vs. 3.0±2.2,
P<.001). Moreover, measuring disability showed that
FMS patients were more severely burdened in daily
activities than were CBP patients (relevant vs. moderated,
respectively, n.s.). FMS patients showed 15.2±2.3 painful
tender points, whereas the CBP group revealed 4.7±3.8
painful tender points (mean±SD).
Comparison of QST Values on the Most Painful
Area in the Back
As shown in Table 2, ANCOVA revealed significant
group differences for all pain thresholds [cold pain thresh-
old (CPT), heat pain threshold (HPT), PPT, and MPT], as
well as for suprathreshold pin-prick pain (MPS) and
vibration detection (VDT). Compared with pain-free
HCs, FMS patients showed higher sensitivity toward cold
and heat pain (CPT P<0.01, HPT, P<0.05) and toward
mechanical pain induced by pin-prick stimulation (MPT
P=0.001, MPS P<0.001) and by blunt pressure (PPT
P=0.001). In addition, CPT (P<0.01), HPT (P<0.05),
and MPT (P<0.01) were lower and MPS (P<0.001)
ratings were higher than those in CBP participants.
Compared with pain-free HCs, CBP participants showed
higher sensitivity with regard to PPT levels (P<0.01) and
lower sensitivity toward VDT (P<0.05).
Comparison of QST Values on Hand Dorsum
As shown in Table 3, ANCOVA revealed significant
group differences for all mechanical pain parameters (MPT,
MPS, and PPT) and for cold pain sensitivity (CPT).
Compared with pain-free HCs, FMS patients showed an
elevated pain sensitivity for pin-prick stimulation (MPT
P<0.01, MPS P<0.01), pressure pain (PPT P<0.05),
and cold pain (CPT P<0.01). Compared with CBP
participants, FMS patients were more sensitive toward
pin-prick pain (MPS P<0.001, MPT P<0.01) and
pressure pain (PPT P=0.001). CBP participants did not
differ from controls with regard to QST values on the hand
dorsum.
Comparison of QST Values With DFNS Reference
Data
A group comparison between FMS patients and pain-
free HCs with regard to DFNS reference data32 revealed a
significantly lower sensitivity to nonpainful warming
(P=0.02) and 5 of 21 FMS individuals ranged outside
the 95% CI of the published reference data. Increased
sensitivity to cold pain (CPT P<0.001), pin-prick pain
(MPT P<0.001, MPS P<0.001), and pressure pain (PPT
P<0.001) was also significantly different from the DFNS
reference data. Several individual values were outside the
95% CI of the published reference data: 4/21 for CPT, 7/21
for MPT, 8/21 for MPS, and 9/21 for PPT.
DMA and PHS
Allodynia on the back occurred in 6 FMS patients, in
none of the back pain participants, and in none of the HCs
(P<0.01, Fisher exact test). On the hand dorsum,
allodynia occurred in 2 FMS patients, in none of the CBP
participants, and in 1 HC (not significant). Because of this
lack of variance, the allodynia score could not be included
in the ANCOVA. Similarly, only 3 FMS patients reported
PHS, 1 on hand dorsum, 1 on the back, and 1 on both sites.
None of the CBP participants and HCs reported PHS.
Localized Versus Generalized Sensory Changes
To distinguish between localized and generalized QST
aberrations, we compared the sensitivity of the hand
dorsum with that of the most painful area in the back. As
there are regional differences between these 2 test sites in
normal participants, the QST values of FMS and CBP
participants were standardized in relation to the QST
values of the pain-free control group using z-transforma-
tion. As allodynia and PHS did not occur in the control
group, the respective values could not be standardized.
TABLE 3. Analysis of Covariance, Mean Values, and Confidence Intervals for Quantitative Sensory Testing of the Dorsum of the Hand
ANCOVA Fibromyalgia Chronic Back Pain Pain-free Controls
F P Mean 95% CI Mean 95% CI Mean 95% CI
CDT D1C 0.187 0.830 1.05 0.84-1.32 1.09 0.90-1.33 1.16 0.93-1.45
WDT D1C 1.44 0.245 2.51 1.86-3.38 1.85 1.42-2.4 1.79 1.33-2.4
CPT 1C 4.73 <0.05 21.03w 17.21-24.85 16.80 13.46-20.14 12.22 8.45-15.98
HPT 1C 0.990 0.378 43.43 41.55-45.32 45.02 43.37-46.68 45.19 43.33-47.06
PPT kPa 6.53 <0.01 238*,J=0.001 204-278 345 301-394 318 273-370
MPT mN 6.18 <0.01 26.73w,y 17.86-39.90 64.27 45.50-90.57 65.01 43.75-96.61
MPS NRS100 10.57 <0.001 2.13z,J 1.24-3.67 0.45 0.28-0.71 0.46 0.27-0.78
WUR 0.764 0.470 3.08 2.27-4.17 3.57 2.74-4.67 2.81 2.07-3.82
MDT mN 0.699 0.502 2.22 1.37-3.60 2.78 1.85-4.18 1.96 1.22-3.16
VDT /8 0.691 0.505 7.90 7.78-8.02 7.97 7.87-8.07 7.89 7.77-8.00
Values of CDT, WDT, PPT, MPT, MPS, WUR, and MDT were calculated by back transformation from the log-means.
*P<0.05 vs. controls.
wP<0.01 vs. controls.
zP<0.001 vs. controls.
Significant test results for fibromyalgia vs. chronic back pain are denoted.
yP<0.01.
JP<0.001, respectively.
CDT indicates cold detection threshold; CI, confidence interval; CPT, cold pain threshold; HPT, heat pain threshold; MDT, mechanical detection
threshold; MPS, mechanical pain sensitivity; MPT, mechanical pain threshold; PPT, pressure pain threshold; VDT, vibration detection threshold; WDT,
warmth detection threshold; WUR, wind-up ratio.
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All other QST parameters were standardized for all
individuals and mean z-scores for both disease groups were
calculated separately (Figs. 1, 2).
FMS patients showed similar QST profiles for both
areas, indicating that their hyperalgesia was generalized and
not local (Fig. 1). WDT was only significantly elevated in
the hand, whereas PPT was decreased significantly more in
the back than in the hand. In addition, there was a
significant difference in WURs, although both areas did not
differ significantly from those of control participants
(Tables 2 and 3). WUR varied around 3.0, but this
variation was in the opposite direction in control partici-
pants. In CBP participants, the lowered vibratory sensitiv-
ity and the enhanced pressure pain sensitivity of the back
were significant compared with the hand, indicating a
localized sensory alteration (Fig. 2). As for FMS, WUR
varied opposite to that of control subjects.
Punctate Mechanical Hyperalgesia
Fibromyalgia patients exhibited an increased pain
sensitivity to pin-prick stimulation (MPT) and enhanced
ratings to pinprick stimuli on a numeric rating scale (MPS),
both on the back and on the hand dorsum. We calculated a
repeated-measure ANCOVA comparing the 3 groups with
regard to MPS, including the single stimulus intensity as a
covariate. We detected overall differences between FMS
patients and both HC and CBP participants (back:
F=18.63 P<0.001; hand dorsum: F=23.93 P<0.001).
These data are analyzed in more detail by plotting
stimulus-response functions for the 7 stimulus intensities
used (Fig. 3). These functions were shifted upward by a
factor of 5. All participants were able to discriminate the
stimulus intensities. There was also a stimulus effect,
indicating higher pain ratings for more intense pin-prick
stimuli. There was no interaction effect between the groups
and the stimulus intensity, indicating that the profiles of the
3 groups are almost parallel (Fig. 3).
DISCUSSION
The present study used a comprehensive QST protocol
to assess the somatosensory profiles of FMS patients, CBP
participants, and HCs. FMS patients showed hyperalgesia
generalized in space and including both superficial and deep
pain modalities, whereas CBP participants revealed a
profile of a localized pain condition with a decreased
threshold only for deep pain and only at the affected area.
Thus, we can conclude that there are distinct sensory
profiles in FMS and CBP participants.
Somatosensory Profiles in FMS
FMS patients showed increased mechanical and
thermal pain sensitivity (with the exception of HPT over
hand dorsum) compared with CBP and HC participants,
FIGURE 3. Stimulus-response functions of pin-prick pain and dynamic mechanical allodynia in the hand and back of patients with
fibromyalgia (closed triangles), chronic back pain (closed circles), and control participants (open circles). Patients with fibromyalgia
exhibit static hyperalgesia to pinprick, both over the pain-free hand and the most painful area of the back. Pain evoked by the same set
of graded punctate probes (numbers indicate force in mN) was about 5-fold stronger in fibromyalgia patients than in chronic back pain
or control participants. Stroking with gentle tactile stimuli (BR, brush; CW, cotton whisp; QT, cotton wool tip) elicited a slight amount of
pain (dynamic mechanical allodynia) in fibromyalgia patients only. Patients with chronic back pain and healthy control participants
showed similar SR functions.
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whereas detection sensitivity was not increased. Our
sensory profile suggests that hyperalgesia in FMS may
involve all nociceptive submodalities. Pin-prick sensitivity
and DMA have not been addressed before. Moreover, pain
sensitivity is increased over back and hand dorsum (parallel
profiles for back and hand in Fig. 1). Thus, increased sensi-
tivity in FMS is generalized in space (superficial and deep
pain, back and hand) and across nociceptive submodalities,
but not to other somatosensory functions. The best possible
explanation for such a generalized hyperalgesia is a
deficient pain inhibitory system.33 Mechanisms of descend-
ing control of pain also include descending facilitation.34,35
The term “central sensitization” often used in the context of
FMS6,14 does not describe the clinical picture sufficiently. It
implies an increased excitability of central neurons, but its
effects are restricted in space to the receptive fields and
often limited to mechanical test stimuli.36,37 Disinhibition,
in contrast, strikes the entire body and may explain a
generalized pain syndrome such as FMS adequately. Thus,
disinhibition should be addressed in future studies.38,39
Possibly, multiple neuronal mechanisms such as disinhibi-
tion, central sensitization, and lack of habituation12 work
together.
The presence of DMA, usually interpreted as an
indicator for a central sensitization of the nociceptive
system, in a relevant number of FMS patients suggests that
a deficit in pain inhibitory systems may facilitate the
occurrence of central sensitization. Yet, this sensory sign
was significantly present only over the back. Sensory
findings on the hand in FMS were characterized by
a pronounced pin-prick hyperalgesia in the absence of
DMA. This type of finding has also been observed in
patients with restless legs syndrome. In restless legs
syndrome, pinprick hyperalgesia is slowly reversed by
dopaminergic treatment.40 Notably, a recent positron
emission tomography study demonstrated a dopaminergic
hyporesponsivity in FMS patients,41 pointing to a
possible pathophysiological commonality between these 2
disorders.
The decreased sensitivity to nonpainful warmth
(WDT) in FMS, which has not been described so far, is
difficult to interpret. In fact, Hurtig et al7 found no
differences in CDT and WDT compared with HCs.
Considering this, the mismatch in age distribution between
FMS patients and HCs has to be taken into account. On
the one hand it is a likely explanation, as the comparison
with age-matched and sex-matched control participants in
the DFNS reference database32 yielded the same result. On
the other hand, however, the difference in WDT was no
longer significant in an ANCOVA with age as a covariate.
A thermal hypoesthesia is usually interpreted as a sign of
disturbed small fiber function, but recently a correlation
between ongoing pain intensity and suppressed sensitivity
to nonpainful thermal stimuli has been reported in chronic
non-neuropathic pain.42 Ongoing pain in FMS patients
may thus contribute to the decreased sensitivity in
nonpainful warmth (WDT) in FMS. Anyway, our data
clearly show that the sensitivity toward nonpainful warmth
is not increased, supporting the view that the elevated
sensitivity in FMS is specific to painful stimuli and not
generalized for all somatosensory stimuli.
The wind-up of pain and wind-up after sensations are
often described in FMS patients10,43 and are thought to
denote altered CNS processing. This feature, however, is
missing in our results, and the WUR for the back was even
lower than that for the hand. Magerl et al44 revealed that, in
a capsaicin model, the difference between the first and last
stimuli of trains of pin-pricks was increased, but the ratio
was unchanged. Our findings are consistent with these
results. FMS patients already rate the first (single) stimulus
significantly higher than do controls or CBP participants,
and thus the relative increase in pain rating after the series
of 10 stimuli is not as high. Hence, wind-up was present in
our FMS patients, but its magnitude was unchanged as the
denominator and numerator of the WUR change by a
similar amount.
Somatosensory Profiles in CBP
In this population-based sample of CBP participants,
we found features of a localized pain condition with no
evidence of spatial generalization, although pain duration
was as long as in FMS patients. Significant differences in
pain thresholds compared with HCs were only seen for
pressure pain, which primarily reflects muscle nociception
and peripheral sensitization.45,46 Moreover, the alterations
were limited to the painful area at the back, meaning that
there were no signs for a pain generalization. CBP
participants differed from FMS patients in all modalities
in the same way as HCs, except for PPT at the back, where
CBP and FMS both showed decreased PPT. These results
suggest localized alterations in muscles and joints. There
was no evidence of central sensitization or disinhibition in
this sample of CBP participants, indicating that chronic
pain per se is not a sufficient condition for these
abnormalities. This finding appears intriguing as other
studies, for example,17 suggested central sensitization in
both FMS and CBP. As our CBP sample was drawn from
the general population, widespread pain sensitivity ob-
served in pain clinic samples may not be representative for
all patients with CBP. Therefore, parameters other than
chronic ongoing nociceptive pain are likely to be the
predisposing factors for widespread pain and FMS. Such
factors may be pain intensity, the subtype of CBP, and
psychosocial factors. In our CBP sample, the average pain
intensity before QST was nearly 50% lower than in the
FMS group. The broad range of pain intensity is probably
due to the heterogeneity of the CBP sample comprising 1
episode of CBP, intermittent, and continuous CBP accord-
ing to the distribution in the general population. This is
consistent with epidemiological data47 showing that only a
subgroup of a population with localized pain developed
FMS later on.
An interesting result was a lower sensitivity toward
vibration at the back of CBP participants. In fact, VDT
was, on average, 6.7/8 in CBP participants, 7.1/8 in FMS
patients, and 7.4/8 in HCs. This result is in line with
secondary tactile hypoesthesia in other painful condi-
tions.48,49 It describes the phenomenon that, in a painful
body area, nonpainful stimuli are suppressed. A recent QST
study showed decreased VDT in patients with pseudo-
radicular back pain as well.50
Technical Considerations
There are several limitations of the study that should
be mentioned. One limitation is the small group size, with
about 20 participants in each group. Further, the groups
significantly differed in age. In future research, it would be
desirable to match patient groups according to age.
However, our results are controlled for age by ANCOVA.
Besides, QST may be described as a “semi-objective”
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procedure, as it still includes the subjective rating of the
participants.51 This raises the question whether QST would
rather measure health behavior than pain thresholds. On
the other hand, we used 2 methods to assess pain thresholds
(method of limits, and direct scaling using randomized
stimuli). Patients with FMS perform consistently at
different body sites in both paradigms and specifically in
the randomized paradigm (Fig. 3). Similarly, brain imaging
techniques with FMS patients show fitting activated areas/
patterns in the brain when compared with QST.17,52
A critical problem consists of the testing sites at the
back. CBP participants suffered from pain especially at the
lower back, whereas FMS patients indicated the most
painful area predominantly at the upper back. The test site
in HCs (trapezius muscle) matches the FMS group better
than the CBP group. Nevertheless, the FMS group had
more sensory aberrations, suggesting that inhomogeneity in
test sites had no major effect on our data. This pitfall
becomes even less important, given that both FMS and
CBP participants revealed abnormal QST profiles at the
painful areas; however, only FMS patients showed
abnormal QST profiles at the pain-free control site as well,
indicating the phenomenon of generalization.
CONCLUSIONS
There is ongoing debate about the classification of
FMS [See discussion in Baillieres Best Practice and
Research: Clinical Rheumatology Vol. 13 (1999)]. Some
authors emphasize the entity of FMS as a distinct and
circumscribed disease53; others argue that FMS is 1 end of a
continuous spectrum of pain diseases.54,55 The other end of
the spectrum may constitute localized pain syndromes such
as CBP. Within this spectrum, a switch between pain
syndromes is possible20,47 and common pathogenetic path-
ways may be assumed. Our data suggest that FMS
pathogenesis may be explained at least partly by disinhibi-
tion, which can explain the spatial generalization of pain
and the involvement of multiple pain modalities. In
contrast, CBP offered features of a local pain condition
with peripheral sensitization. Given that pain duration did
not differ in CBP participants and FMS patients, our
population-based data suggest that CBP may persist as a
localized pain condition for many years without turning
into widespread pain or FMS. Thus, if CBP is a pre-stage to
FMS and findings show involvement of central nervous
pathways in some patients, as observed in pain clinics,
factors other than ongoing peripheral nociceptive pain itself
are likely to account for this generalization in place of the
ongoing pain.
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a b s t r a c t
There is evidence for long-term alterations in pain tolerance among athletes compared with normally
active controls. However, scientific data on pain thresholds in this population are inconsistent, and the
underlying mechanisms for the differences remain unclear. Therefore, we assessed differences and sim-
ilarities in pain perception and conditioned pain modulation (CPM) at rest in endurance athletes and nor-
mally active controls.
The standardised quantitative sensory testing protocol (QST) of the ‘German-Research-Network-on-
Neuropathic-Pain’ was used to obtain comprehensive profiles on somatosensory functions. The protocol
consisted of thermal and mechanical detection as well as pain thresholds, vibration thresholds, and pain
sensitivity to sharp and blunt mechanical stimuli. CPM (the diffuse-noxious-inhibitory-control-like
effect) was measured using 2 tonic heat pain test stimuli (at the temperature exceeding a subjective pain
rating of 50/100) separated by a 2-min cold-pressor task (CPM-TASK; conditioning stimulus). Pain ratings
were measured with a numerical rating scale. Endurance capacity was validated by assessment of max-
imum oxygen uptake (VO2max). Participants included 25 pain-free male endurance athletes
(VO2max > 60 mL/min ⁄ kg) and 26 pain-free normally active controls (VO2max < 45 mL/min ⁄ kg)
matched based on age and body mass index.
Athletes were significantly less sensitive to mechanical pain but showed higher sensitivity to vibration
(P < 0.05). In athletes, CPM was significantly less activated by the conditioning stimuli (P < 0.05) when
compared with normally active controls.
Our data show that somatosensory processing in athletes differs in comparison with controls, and sug-
gest that the endogenous pain inhibitory system may be less responsive. This finding may explain the
paradoxical propensity of athletes to develop chronic widespread pain.
Ó 2013 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
1. Introduction
Pain is a common phenomenon in athletes [3,22,26,51,60,67].
This is paradoxical, as physical activity is part of most multimodal
pain treatment programmes. Thus, on the one hand, physical activ-
ity might be the origin of a variety of pain syndromes in athletes
who engage in rigorous physical activity [3,22,26,51,60,67],
whereas on the other hand, physical activity also represents an
important therapeutic concept in pain syndromes [20,21,43,55].
Therefore, increased knowledge concerning the role of physical
activity on pain perception and processing may impact the medical
care of pain patients in general, and athletes in particular.
There has been consistent evidence that after an episode of in-
tense exercise, pain perception is reduced for a limited period of
time, i.e., ‘acute exercise-induced analgesia’ [29,31]. It has been
theorised that physical activity activates some generalised endog-
enous pain-modulatory mechanisms, e.g., conditioned pain modu-
lation (CPM; formerly termed ‘diffuse noxious inhibitory control’)
[5,29], baroreflex-mediated analgesia [7,30], stress-induced hypo-
algesia [29], or attentional factors [29,31]. Although different
mechanisms have been proposed [29,30], CPM is of special interest,
as alterations in this system have been reported for a variety of
chronic pain conditions [19,27,28,36,40,41,44,63,71]. Moreover, a
deficit in this system is associated with chronic widespread pain
(CWP) [44], which is frequently reported in athletes (prevalence
31% [23]).
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To date, research has focused on pain perception during physi-
cal activity rather than the potential long-term consequences of
regular exposure to physical activity on pain processing at rest.
In particular, the endogenous pain inhibitory system is a little-re-
searched issue in athletes and, to date, no data have been pub-
lished about CPM.
Researchers have postulated that long lasting physical activity
may alter pain perception at rest and have often concluded that
athletes possess higher pain thresholds and a higher pain tolerance
in general [50,53]. A recent meta-analysis confirmed significantly
higher pain tolerance in athletes at rest and specific alterations
in pain thresholds [57]. But, although some studies have reported
elevated pain tolerance or pain thresholds [16,18,56], there are also
data demonstrating normal [49] or even lower [45] pain thresholds
in athletes. This ambiguity may be because different pain induction
methods with non-standardised and non-validated testing para-
digms have been used [10,11,16,18,45,49,50,66]. The situation is
aggravated because the definition of an athlete in most pain stud-
ies has been characterised arbitrarily, and to date, there are almost
no pain studies in which physical fitness has been assessed objec-
tively [57].
To overcome some of these shortcomings, this study assessed
for the first time pain perception and endogenous pain modulation
in athletes using a comprehensive standardised quantitative sen-
sory testing protocol (QST [47]) and an objective evaluation of
‘physical fitness.’ The aim of this study was (1) to examine whether
there are differences in pain perception at rest between athletes
and normally active controls, and if so, (2) to determine if endoge-
nous pain-modulating mechanisms are involved. It was predicted
that athletes are characterised by specific sensory profiles and that
the endogenous pain modulation of athletes is significantly differ-
ent compared with normally active controls.
2. Methods
2.1. Study population
In the present study, 25 endurance athletes and 26 normally ac-
tive controls were included. Athletes were recruited from regional
sport clubs. Healthy normally active controls were recruited via
flyers posted in the local community. Inclusion criteria were as fol-
lows: male sex, age 18-35, and without pain. The study sample was
restricted with respect to sex and age, as QST and CPM are sex-
[9,46] and age-dependent [8,48]. Athletes trained for at least 3 h/
wk for more than 3 years and were characterised by a maximal
oxygen consumption (VO2max) >60 mL/min ⁄ kg. Controls were
age- and BMI-matched, did not engage in regular physical activity,
and had a VO2max < 45 mL/min ⁄ kg.
Study participants were screened using a questionnaire, physi-
cal examination, and electrocardiogram to rule out acute or chronic
pain; in addition, data concerning regular medication use, diseases
affecting sensory processing (e.g., diabetes, polyneuropathy) or
contraindications to treadmill testing were used to screen patients.
Subjects were excluded if they reported any history of injury of the
hand dorsum or arm, as this was the area tested in our paradigm.
Participants were advised not to take any medication 24 h prior to
the investigation and to refrain from intensive or prolonged train-
ing on the day prior to each test.
2.2. Instruments
2.2.1. Assessment of athletic performance
Maximal oxygen consumption (VO2max, mL/min ⁄ kg) was
measured in a ramp protocol on a motor-driven treadmill (Quasar
med, H/P/Cosmos, Traunstein, Germany). After warming-up for
2 min at 4 km/h at an incline of 1.5%, the test began at a speed of
7.2 km/h, and the speed was increased by 0.6 km/h over 30 s until
volitional exhaustion. Oxygen consumption was measured using a
metabolic card (Ergostik, Geratherm Respiratory GmbH, Bad Kiss-
ingen, Germany). VO2 max related to body weight was considered
to be the highest VO2 over a period of 30 s during the test. Prior to
each test, both sensors were calibrated according to the manufac-
turer‘s instructions. During the treadmill test, a continuous 12-lead
ECG was recorded.
Specifications of physical activity were also captured using a
questionnaire that included a detailed self-report of the type, fre-
quency, intensity, and duration of physical activities.
2.2.2. Assessment of pain perception
Somatosensory function was assessed using the comprehensive
QST protocol, which was developed as part of the German Research
Network on Neuropathic Pain (DFNS) [47]. It covers all relevant as-
pects of the somatosensory system, including large and small fibre
functions, and signs of central sensitisation (dynamic tactile allo-
dynia, punctate mechanical hyperalgesia, and paradoxical heat
sensations). In this manner, detailed profiles of somatosensory
function for the tested body areas were obtained. The dorsum of
the dominant hand was tested.
To familiarise participants with the test procedure, all tests
were first conducted over an area that was not tested later during
the QST session.
The tests for thermal detection thresholds (warm detection
threshold, WDT, and cold detection threshold, CDT), thermal pain
thresholds (heat pain threshold, HPT, and cold pain threshold,
CPT), and paradoxical heat sensations (PHS) were conducted using
a TSA 2001-II (MEDOC, Israel) thermal sensory testing device [72].
All thresholds were obtained using ramped stimuli (1°C/s, 32°C
baseline, 0°C and 50°C cut-offs, 8 cm2 thermode), which were ter-
minated when participants pressed a button. The mean of 3 con-
secutive measurements was calculated. Thermal sensory limen
(TSL), a test with alternating warming and cooling ramps, was used
as a provocative test to induce PHS.
The mechanical detection threshold (MDT) was measured with
a standardised set of modified von Frey filaments (Optihair2-Set,
Marstock Nervetest, Germany), which exert forces between 0.25
and 256 mN [13]. The contact area was of uniform size and shape
(round, 0.5 mm diameter). The threshold was the geometric mean
of 5 series of ascending and descending stimulus intensities.
The mechanical pain threshold (MPT) was measured using a set
of weighted pinprick stimulators with a flat contact area of
0.25 mm diameter, which exert forces between 8 and 512 mN
[4]. Again, using the method of limits, the threshold was the geo-
metric mean of 5 series of ascending and descending stimulus
intensities.
Mechanical pain sensitivity (MPS) was tested using the same
weighted pinprick stimuli as that for MPT. To obtain stimulus re-
sponse function, these 7 pinpricks were applied in balanced order
5 times each. The participant was asked to rate each stimulus for
pain on a 0 to 100 numerical rating scale (0 indicating ‘no pain,’
and 100 indicating ‘most intense pain imaginable’). The geometric
mean of the 35 pain ratings was the final value for MPS. Stimulus
response functions for dynamic mechanical allodynia (DMA) were
determined using a set of 3 light tactile stimulators [4,34]. They
were intermingled with the pinprick stimuli in a balanced order,
and participants were asked to give a rating on the same numeric
rating scale.
The vibration detection threshold (VDT) was determined with a
Rydel-Seiffer tuning fork (64 Hz, 8/8 scale), which was placed over
the bony prominence of the processus styloideus radii of the dom-
inant hand 3 times. Subjects indicated the time at which they no
longer experienced vibratory sensations.
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2.2.3. Assessment of conditioned pain modulation
To test CPM (the term CPM rather than diffuse noxious inhib-
itory control/DNIC is chosen based on the recent recommenda-
tions of Yarnitsky et al. [70]), we used the protocol of
Tousignant-Laflamme et al. [59] and consulted the guidelines
for the cold-pressor task (CPM-TASK) as an experimental pain
stimulus [65]. The CPM-TASK activates the diffuse noxious inhib-
itory control-like effect (CPM), as it is a strong nociceptive stimuli
that takes place over a lengthy span of time [69] and is applied
over a large body surface area [39]. Thus, the CPM-TASK allows
us to modify the endogenous pain-modulating system. To quan-
tify CPM, we evaluated the pain intensity of two tonic heat pain
(THP) test stimuli separated by a CPM-TASK. Even if the THP
may lead to both habituation and sensitisation according to the
dual process theory, the THP is a reliable stimulus to induce
CPM [59].
CPM-TASK: The cold-pressor task was used as a conditioning
stimulus to elicit a strong and prolonged pain sensation to trigger
CPM. The CPM-TASK consisted of immersing the non-dominant
hand and wrist and approximately 5 cm of the forearm in circulat-
ing cold water (22 L + circulating with 15 L/min) for 2 min (in-
formed ceiling task). To maintain the water temperature at
12 ± 0.2°C, we used an immersion cooler and a thermostat to con-
trol for temperature variations in both directions (Immersion cool-
er FT 200 and clip thermostat model ED, Julabo, Seelbach,
Germany). The temperature of the water was set at 12°C to ensure
that the CPM-TASK was sufficiently painful to elicit CPM while tol-
erable enough to be endured for 2 min. To control depth of immer-
sion, the hand was placed on a grid (rubber isolated metal grid)
that permitted the circulation of water on all sides of the immersed
hand. Participants were instructed to lay their hand loosely on the
grid and were asked to not move the hand or explore their grid. An
armrest of silicone made testing more comfortable and prevented
participants from changing the depth of immersion. During the
test, subjects verbally rated their pain intensity every 5 s using
the numerical rating scale (NRS0/100). The rating scale ranged from
0, i.e., ‘no pain,’ to 100, i.e., ‘most intense pain imaginable.’ The
experimental setup was approved by our local medical engineering
department.
THP: To determine the temperature for the 2-min THP, an ini-
tial pre-test was completed. To familiarise participants with the
testing procedure, participants were asked to continuously rate
their pain intensity using the NRS0/100, while the temperature of
the thermode was gradually increased from 32°C to 50°C (0.3°C/
s). The procedure was conducted twice. After participants were
acclimated to the procedure and after a short break, we deter-
mined the temperature at which participants rated the THP with
a score of 50/100 (0 ‘no pain’ to 100 ‘most intense pain imagin-
able’). This procedure was performed until the temperature in 2
consecutive runs did not differ by more than ±1°C. The mean
temperature eliciting pain ratings of 50/100 on the NRS0/100
(Temp50) was used for the THP. After a short break, the first
THP (Pain baseline, THP0) was applied to the palm of the domi-
nant forearm (Peltier Thermode, TSA II, Medoc, Advanced medical
systems, Israel). Participants were instructed that the tempera-
ture could increase, decrease, or remain constant. Then, the tem-
perature of the thermode was increased from 32°C at a rate of
0.3°C/s to the individually determined temperature. Thereafter,
the pain stimulus remained constant for 2 min. Pain intensity
was measured every 5 s using the NRS0/100. Following the first
THP (THP0), the CPM-TASK was used to trigger CPM. One minute
after the CPM-TASK, we applied the second THP (THP1). We quan-
tified the amount of CPM by subtracting the mean pain rating of
the first THP before the CPM-TASK (THP0) from the second THP
after the CPM-TASK (THP1).
2.2.4. Assessment of pain experience
To evaluate different aspects of the pain experience, the Pain
Experience Scale (‘Schmerzempfindungsskala,’ SES), a well-vali-
dated instrument used in pain research, was administered. The
SES consists of 24 items and distinguishes between the affective
and sensory dimensions of pain [14]. The response format was 4-
staged, from 1 ‘not applicable,’ to 4 ‘absolutely applicable.’ To cal-
culate values for the affective (items 1–14, e.g., ‘‘exhausting,’’
‘cruel’) and sensory (items 15–24, e.g., ‘hot,’ ‘stabbing’) subscales,
items for each subscale were summed. We asked participants to
rate the SES after assessment of CPM. Participants were instructed
to rate ‘pain sensations during testing.’ The SES is sensitive to
change and has proven validity and reliability for the affective
and sensory subscales (a = 0.81 and 0.92 respectively) [14].
2.3. Study design
All tests were performed at the same time in the afternoon. Be-
fore starting the tests, the subjects rested for half an hour in their
respective environments. The test procedure began with the QST
protocol and was followed by an assessment of conditioned pain
modulation. Directly after the assessment of CPM, pain experience
was evaluated with the SES. Maximal oxygen consumption was
determined 30 min after the pain assessment procedure. The pres-
ent study was approved by the Ethics Research Committee of the
Faculty of Medicine, University of Heidelberg and was carried out
in accordance with the Declaration of Helsinki. All participants
gave written informed consent and received an allowance of 30
Euros (approximately 40 dollars) for their participation.
2.4. Statistical analysis
All analyses were conducted using SPSS for Windows (Version
19.0). Descriptive statistics are presented as the means and stan-
dard deviations for continuous variables, and absolute numbers
and percentages for categorical variables. All analyses were explor-
ative and not of confirmatory nature.
CPM was determined by subtracting the mean pain intensity of
the THP prior to the CPM-TASK from the mean pain intensity of the
THP after the CPM-TASK. Therefore, negative values indicate inhib-
itory conditioned pain modulation. Between group differences
with respect to the CPMwere tested using t tests, and paired t tests
were used to determine within group differences. Variables that
exhibited a non-normal distribution were analysed using non-
parametric Mann–Whitney U tests. Most QST parameters (CDT,
WDT, TSL, MPT, MPS, DMA, WUR, PPT, and MDT) are log-normally
distributed and were therefore log-transformed [47]. Group differ-
ences between athletes and normally active controls were tested
using t tests. We also standardised all QST measures of athletes
using a z-transformation referring to the mean and standard devi-
ation of the control group. This procedure allowed for direct com-
parison between sensory tests that are measured in different units
(e.g., °C and mN) as well as judgement of a gain or loss of function
in profiles between athletes and normally active controls. Hyper-
function is indicated by z-values above ‘0,’ i.e., patients are more
sensitive to the tested parameter compared with controls (lower
thresholds, gain of function), whereas z-scores below ‘0’ indicate
hypofunction and therefore a loss of or lower sensitivity of the pa-
tient compared with controls (higher thresholds). Whenever log-
transformed scores were calculated, the log-scores were used for
z-standardisation and t tests.
Because of the explorative nature of the study, we abstained
from adjustment for multiple testing and interpreted P-values cau-
tiously as descriptive measures of effect. Statistical significance
was accepted if P < 0.05.
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3. Results
3.1. Subjects
A total of 25 male endurance athletes (14 triathletes, 10 run-
ners, and 1 cyclist) and 26 age- and BMI-matched normally active
subjects were included in the analysis. Descriptive statistics for
demographic and clinical variables are summarised in Table 1. Ath-
letes were characterised by a mean training time of 9.6 ± 3.5 h/wk
and a mean frequency of 5.4 ± 1.6 training d/wk. All athletes had
participated regularly in competitions during the previous 3 years.
Maximal oxygen uptake (VO2max) was significantly higher (62%)
in athletes compared with normally active controls
(65.9 ± 4.6 mL/min ⁄ kg and 40.6 ± 6.2 mL/min ⁄ kg, respectively,
P < 0.001). Values indicate a highly trained population of athletes,
whereas normally active controls were characterised by an appro-
priate level of inactivity. There were no significant differences in
age, BMI, or skin temperature between athletes and normally ac-
tive controls. In control subjects, 21 of the 286 QST parameters
were outside the published reference range for age- and gender-
matched subjects [37], which is close to the expected value of
5%. That about 5% are outside the published reference data range
indicates that our controls are representative for the published ref-
erence data of healthy controls, and thus underpins the represen-
tativeness and quality of our data [37].
3.2. Comparison of QST values
As shown in Table 2 and Fig. 1, t tests revealed significant group
differences for the mechanical pain threshold (MPT) and for the
vibration detection threshold (VDT). Compared with normally ac-
tive controls, athletes showed an elevated pain threshold with re-
spect to pinprick stimulation (MPT: P < 0.05), but increased
sensitivity to vibration stimuli (VDT: P < 0.05). Athletes did not dif-
fer significantly from controls for cold and heat stimuli (CDT, WDT,
CPT, HPT, and TSL), non-painful mechanical stimuli (MDT),
mechanical pain sensitivity (MPS), and mechanical pain induced
by blunt pressure (PPT).
To validate the results for MPT, post hoc analysis for mechanical
pain sensitivity stratified for stimulus-force revealed that athletes
were less sensitive to low stimulus intensities but did not differ
for higher stimulus intensities. Therefore, as differences were re-
stricted only to the lower forces and not to higher stimulus inten-
sities, group differences in MPS did not reach the level of
significance. Analysis for outliers showed that 1 subject in the con-
trol group had an MPT outside the 95% confidence interval (CI).
This highlights the validity of a loss of function among the athlete
group, indicating that the results were not based on pathological
outliers. With respect to VDT, 1 control subject and 1 athlete re-
ported a loss of function that was outside the 95% CI. This also
highlights the validity of the gain of function in athletes, as it is
not explainable by outliers within the respective groups. Correla-
tion analyses of VO2max with sensory parameters revealed a sig-
nificant correlation only for VDT (r = 0.419, P = 0.008).
No signs of central sensitisation (dynamic tactile allodynia,
punctate mechanical hyperalgesia or paradoxical heat sensations)
were found for athletes or the control group. In addition, there
was no difference in the temporal summation of pain (WUR) be-
tween the 2 groups.
Table 1
Demographic and clinical variables of athletes and controls.
Athletes (n = 25) Controls (n = 26) P-value
Age (years) 27.8 ± 4.1 28.0 ± 4.5 0.920
BMI (kg/m2) 22.1 ± 1.5 22.7 ± 2.2 0.229
VO2max (mL/min ⁄ kg) 65.9 ± 4.6 40.6 ± 6.2 <0.001
VCO2max (mL/min ⁄ kg) 5.4 ± 0.5 3.8 ± 0.6 <0.001
VE (L/min) 158 ± 17 115 ± 24 <0.001
Training hours (h/wk) 9.6 ± 3.5 <0.5 <0.001
Number of training (d/wk) 5.4 ± 1.6 – –
Training since when (mo) 119.6 ± 82.9 – –
BMI, body mass index; VO2max, maximal oxygen uptake; VCO2 max, maximal carbon dioxide production; VE, maximal air ventilation.
Data are indicated as the mean ± standard deviation.
A two-tailed Student t test was used to determine level of significance.
Table 2
Somatosensory profiles obtained by quantitative sensory testing of athletes and
normally active healthy controls.
Athletes Controls ES P-value
Mean SD Mean SD
CDT D° ÿ0.03 0.26 ÿ0.02 0.17 ÿ0.05 0.931
WDT D° 0.19 0.25 0.17 0.22 ÿ0.09 0.771
TSL °C 0.35 0.23 0.32 0.24 ÿ0.13 0.725
CPT °C 11.35 10.66 15.79 10.43 ÿ0.42 0.148
HPT °C 44.06 3.87 43.44 4.08 ÿ0.16 0.581
PPT kPa 2.58 0.14 2.55 0.12 ÿ0.23 0.332
MPT mN 1.92 0.53 1.58 0.49 ÿ0.67 0.027
MPS NRS0/100 ÿ0.18 0.38 -0.02 0.44 ÿ0.4 0.187
WUR 0.34 0.23 0.41 0.3 ÿ0.26 0.356
MDT mN 0.15 0.5 0.11 0.38 ÿ0.09 0.72
VDT /8 7.81 0.29 7.58 0.46 0.61 0.047
CDT, cold detection threshold; WDT, warm detection threshold; TSL, thermal sen-
sory limen; CPT, cold pain threshold; HPT, heat pain threshold; PPT, pressure pain
threshold; MPT, mechanical pain threshold; MPS, mechanical pain sensitivity;
WUR, wind-up ratio; MDT, mechanical detection threshold; VDT, vibration detec-
tion threshold; NRS0/100, numeric rating scale; mN, millinewton; kPa, kilopascal.
Data are given as log-transformed values (mean ± SD) except PHS, HPT, CPT, and
VDT, which are listed as absolute values according to [43].
Two-tailed Student t test was used to determine level of significance.
Effect sizes (ES) were calculated as Hedge’s g.
Fig. 1. Quantitative sensory testing (QST) profiles in athletes. Somatosensory
profiles at hand dorsum in athletes. Values are mean ± SEM. To obtain z-values,
athletes’ values were standardised according to mean and standard deviation of
normally active controls. ⁄P < 0.05, t test vs normally active controls. CDT, cold
detection threshold; WDT, warm detection threshold; TSL, thermal sensory limen;
CPT, cold pain threshold; HPT, heat pain threshold; PPT, pressure pain threshold;
MPT, mechanical pain threshold; MPS, mechanical pain sensitivity; WUR, wind-up
ratio; MDT, mechanical detection threshold; VDT, vibration detection threshold.
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However, although the majority of differences did not reach the
conventional level of significance, there were trends for signifi-
cance for all of these variables towards a loss of function (hypoes-
thesia, hypoalgesia) in athletes.
3.3. Comparison of conditioned pain modulation (CPM)
Table 3 shows that there was a significant difference in CPM be-
tween athletes and normally active controls (P < 0.05). There was a
strong activation of CPM by the CPM-TASK in controls (P < 0.001),
whereas CPM was only slightly induced by CPM-TASK in athletes
(P = 0.091, Fig. 2). The effect size of the CPM on the differences in
mean THP ratings before and after the CPM-TASK was small in ath-
letes (Cohen’s d = 0.14), whereas the inhibitory effects of this par-
adigm in controls were characterised by a moderate effect size
(Cohen’s d = 0.55).
There were no significant differences in the temperature of the
Temp50 stimulus (P = 0.212), the mean THP pain ratings prior to the
CPM-TASK (P = 0.411) or in the mean pain rating for the CPM-TASK
(conditioning stimulus, P = 0.088). However, because of the mar-
ginal difference in CPM-TASK ratings between athletes and nor-
mally active controls, we repeated the analysis for CPM and
entered the CPM-TASK pain intensity as a covariate in the analysis
of covariance. Differences in CPM, with less activity activated in
athletes, remained significant (P < 0.05) even after controlling for
CPM-TASK pain intensity. The intensity of the CPM-TASK was not
significantly associated with CPM. Correlation analysis of CPMwith
CPM-TASK pain intensity (r = 0.032, P = 0.833) or with VO2max
(r = 0.161, P = 0.348) showed no association. Athletes and controls
did not differ in THP0. None of the participants attained complete
pain relief after conditioning stimulus. Exploratory analysis
showed that in the control group there was a gain in 3 subjects
and a loss in 20 subjects, whereas in athletes there was a gain in
7 subjects and a loss in 16 subjects. Outlier analysis revealed that
in each group, 1 subject experienced a gain and 1 loss of function
outside the 95% CI. This confirms the validity of the results.
3.4. Pain experience
Concerning differences in pain experience, assessed by the SES,
there were no differences in affective (athletes: 20.1 ± 5.8, con-
trols: 20.7 ± 6.3, P = 0.762, possible range 10–40) or sensory (ath-
letes: 18.2 ± 4.3, controls: 18.5 ± 4.9, P = 0.792, possible range 14–
56) pain experience for modified pain at T1 (THP1) between ath-
letes and normally active controls after the induction of CPM.
4. Discussion
This study has shown decreased sensitivity for MPT, increased
sensitivity to vibration and a reduction in CPM in endurance ath-
letes with validated athletic status.
No significant differences were found for heat, cold or pressure
pain thresholds, or for temperature and mechanical detection
thresholds. These findings are consistent with previous work,
which also found no differences for heat [52,54] or pressure pain
thresholds between athletes and normally active controls [38,49].
4.1. Sensory profiles in endurance athletes
The isolated loss of function for pinprick stimuli described in
this study is an interesting finding, as MPT by pinprick has not
been tested in athletes to date. An increase in MPT can result from
both dysfunctions of the peripheral nociceptors and inhibition
within the central nervous system [62,73]. The peripheral sensors
for pinprick stimuli are a highly specific class of high threshold
Ad-mechanoreceptors with high relevance for protective guarding
and withdrawal behaviour [61,73]. Alterations in peripheral noci-
ceptors seem to be consistent with previous research, which has
found abnormal nerve-conduction-tests in runners, suggesting
asymptomatic neuropathy similar to that noted in subclinical
entrapment neuropathy [6]. However, these data were restricted
to the lower extremities of runners, whereas our data focused on
the upper extremity. Moreover, researchers have not studied the
peripheral nervous system in athletes systematically, and future
studies on peripheral nociceptor function in athletes are
recommended.
Table 3
Conditioned pain modulation in athletes and normally active controls.
Athletes (n = 25) Controls (n = 26) P-value
Pain baseline T0 (THP0) (NRS0/100) 34.2 ± 21.9 38.8 ± 15.7 0.411
Conditioned pain modulation (CPM) (T1ÿT0) ÿ3.1 ± 8.7 ÿ9.6 ± 12.2 0.020
a
Pain CPM-TASK (NRS0/100) 58.6 ± 24.0 68.9 ± 15.6 0.088
Data are indicated as the mean ± standard deviation.
THP: the tonic heat pain stimulus was applied as test stimulus at individual determined temperature (temperature at which participants rated the THP
with 50 of 100 on the NRS0/100) for 2 min by a thermode on the palm of the dominant forearm.
Conditioned pain modulation (CPM): CPMwas quantified by subtracting the mean pain rating of the first THP (THP0) before the CPM-TASK from the second
THP (THP1) after the CPM-TASK. Therefore, negative values indicate inhibitory CPM.
CPM-TASK: pain ratings during the cold-pressor task; the CPM-TASK as conditioning stimulus consisted in the immersion of the non-dominant hand for
2 min in circulating 12°C cold water.
Variables that were normally distributed were analysed using independent samples t test, whereas variables that exhibited non-normal distribution were
analysed using non-parametric Mann–Whitney U tests (a). Difference in CPM remained significant (P < 0.05) even after controlling for cold-pressor test
pain intensity.
Fig. 2. Conditioned pain modulation (CPM). Reduction in pain intensity (condi-
tioned pain modulation) between thermal pain measures (test stimulus) obtained
before and after the cold-pressor task (CPM-TASK, conditioning stimulus). Controls
(n = 26) had a 25% reduction (Cohen’s d = 0.55) in thermal pain following the CPM-
TASK, whereas there was only a small change (9%, Cohen’s d = 0.14) for athletes
(n = 25). ⁄P < 0.05.
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It is notable that most QST parameters showed a general trend
towards a reduced sensitivity, indicating a ‘loss of function’,
although the level of statistical significance was reached only for
MPT.
It has been suggested that perception aberrations in athletes
may be based on their lack of motivation (‘stoicism’) to report pain
[24,25]. In this regard, ‘stoic athletes’ should feel as much pain as
others but express their experience less. Therefore, if athletes offer
fewer reports of pain, they would also experience a (pseudo-
)reduction in their sensory response to noxious stimuli. In our
study, pain reports relied on subjective pain ratings and may there-
fore have given the appearance of increased pain thresholds.
Although there was a trend towards a ‘loss of function,’ the QST
profiles observed in our study did not generally support the idea
of stoicism to pain in athletes for several reasons. First, detection
thresholds were shifted toward a loss of function in our study;
however, detection thresholds do not exceed pain and therefore
should not be affected by stoicism [24,25]. In addition, there was
no difference in the affective dimension of pain experience be-
tween athletes and normally active controls as one might expect
in the case of stoicism. Moreover, there was a significant decrease
in VDT, suggesting that athletes were more sensitive to the detec-
tion of vibration than normally active controls.
The increased sensitivity to vibration is an interesting finding,
as the vibration detection threshold was the only measure that
was altered toward a gain of function (more sensitive perception).
Vibration results in a small variation in muscle length, thereby
activating low-threshold muscle spindle proprioceptors [12,64].
Decreased vibration-detection thresholds indicate an increased
excitability of those non-pain-encoding proprioceptors or of the
respective central projection pathways. There is evidence that
vibration perception is associated with postural control [32,33].
Postural control is an important feature of the athlete’s compe-
tence, and therefore specifically trained in athletes. In this regard,
enhanced vibration sensitivity may be the result of a well-trained
locomotive system. As a defective locomotive system is a key factor
in the pathophysiology of restless leg syndrome, it is interesting to
note that an increased sensitivity to vibration has also been dem-
onstrated for patients suffering from restless leg syndrome [2].
However, this assertion is speculative, and further research is
needed to better understand the underlying mechanisms.
4.2. Reduced CPM in athletes
Athletes were characterised by a significantly lower activation
of the CPM induced by the CPM-TASK than normally active con-
trols. Although, there is consistent evidence that intense physical
activity results in the direct activation of endogenous pain inhibi-
tion for a limited period of time [29–31], the long-term conse-
quences of the chronic activation of this system by regular high
performance exercise have not been investigated thus far.
One possible explanation may be that tonically increased acti-
vation levels of the endogenous pain inhibitory system in athletes
result in a ceiling effect: because of the continuous and heightened
activation level of endogenous pain inhibition, additional activa-
tion as induced by the CPM-TASK may be truncated, and athletes
failed to respond adequately when directly challenged using the
CPM-paradigm. The ‘elevated activation level hypothesis’ of inhib-
itory pain control in athletes is consistent with our observation
that all QST parameters, with the exception of VDT, showed a gen-
eral trend towards reduced sensitivity. The constant activation of
the descending pain inhibitory system in athletes might be the
compensatory response to repeated noxious input induced by reg-
ular exhaustive training in these subjects. Without such continu-
ous counter-regulatory pain inhibitory activity, athletes might
not be able to endure daily physical activity.
Alternatively, there may be a shift in the activation threshold of
the endogenous pain inhibitory system in athletes. The ‘threshold
hypothesis’ postulates that the pain inhibitory system in athletes
require higher stimuli to get activated or, using fixed stimulus
intensity, the same stimulus will result in a lower activation of
the pain inhibitory system in these subjects.
One may argue that it is easy to test this hypothesis directly by
using more painful stimuli as conditioning stimuli. However, in-
creased noxiousness of the conditioning stimuli results in an in-
creased drop-out rate of subjects who are sensitive to pain, thus
leading to a strong selection bias for the overall results. Neverthe-
less, the hypothesis is supported indirectly by the finding that the
correlation between cold-pressor associated pain intensity and in-
duced CPMwas higher in the athlete group than for the entire sam-
ple (r = 0.222 vs r = 0.032). Accordingly, this might indicate that in
some athletes the threshold to activate the CPM was not reached.
As chronic widespread pain, which is not rare in athletes [23], is
often explained by exhaustion of CPM [44], the hypothesis of an
elevated activation level may contain an interesting approach for
future research on pain in athletes.
Notably, at present there are no accepted standards for the per-
formance of CPM. There are different studies using either tonic
[17,28,44,58,68] or phasic stimuli [1,15,35]. As the paradigm used
in this study was based on a tonic heat stimulus as test stimulus,
our findings cannot be extrapolated offhandedly to other kinds of
stimuli. Further research is needed using other paradigms (e.g.,
phasic test stimuli) to induce such modulation, which might show
different aspects of these systems, and, possibly, different clinical
correlates.
4.3. Limitations
Limitations include lack of statistical power as a result of small
sample sizes as well as risk of false positive results. Based on our
explorative-descriptive approach, P-values should be interpreted
more as a descriptive measure of effect than as a confirmatory
judgement.
In addition, with the use of sensory measures at or near thresh-
old to characterise pain sensitivity, the findings might not be trans-
ferable to pain tolerance. Moreover, the generalisability of our
results to athletes in general is limited, as our study was restricted
to male endurance athletes, accordingly, our results may not be
representative for female athletes nor for other kind of sports
(e.g., game or strength sports). Furthermore, although our athletes
were characterised by both outstanding physical fitness and regu-
lar participation in official competitions, it should also be borne in
mind, that ‘athleticism’ was not assessed explicitly in our study.
At last, determining the direction of causality of our findings is
not possible given our study design. Whether athletes acquire al-
tered pain perception because they engage in physical activity or
whether they are able to engage in physical activity as a result of
altered pain perception requires further longitudinal research.
4.4. Conclusions
The proposed alterations in endogenous pain modulation noted
in our study may have consequences for future research. For exam-
ple, various pain alleviating medications reduce pain through acti-
vation of pain-inhibitory circuits [42] and may therefore act
differentially in athletes. Moreover, a chronic overstressing of the
endogenous pain inhibitory pathways by heightened activation
levels may eventually result in exhaustion over time. Such exhaus-
tion may result in disinhibition of pain processing and in transition
from acute to chronic pain conditions as well as spatial pain
spreading, which are both common problems in athletes
[33,22,26,51,60,67]. In contrast, a shift in the activation threshold
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may protect the endogenous pain inhibitory pathways from
chronic overstressing over the course of time and may thus con-
tribute to an increase in the efficiency of pain inhibition on a
continuing basis.
Together, the results of this research support the idea that ath-
letes generally differ from non-athletes with respect to pain per-
ception as well as pain processing and suggest a compensatory
response of the endogenous antinociceptive system to the repeated
noxious input induced by the regular exhaustive training in endur-
ance athletes.
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Abstract
Background: Pain conditions of the musculoskeletal system are very common and have tremendous
socioeconomic impact. Despite its high prevalence, musculoskeletal pain remains poorly understood and
predominantly non-specifically and insufficiently treated.
The group of chronic musculoskeletal pain patients is supposed to be heterogeneous, due to a multitude of
mechanisms involved in chronic pain. Psychological variables, psychophysiological processes, and neuroendocrine
alterations are expected to be involved. Thus far, studies on musculoskeletal pain have predominantly focused on
the general aspects of pain processing, thus neglecting the heterogeneity of patients with musculoskeletal pain.
Consequently, there is a need for studies that comprise a multitude of mechanisms that are potentially involved in
the chronicity and spread of pain. This need might foster research and facilitate a better pathophysiological
understanding of the condition, thereby promoting the development of specific mechanism-based treatments for
chronic pain. Therefore, the objectives of this study are as follows: 1) identify and describe subgroups of patients
with musculoskeletal pain with regard to clinical manifestations (including mental co-morbidity) and 2) investigate
whether distinct sensory profiles or 3) distinct plasma levels of pain-related parameters due to different underlying
mechanisms can be distinguished in various subgroups of pain patients.
Methods/Design: We will examine a population-based chronic pain sample (n = 100), a clinical tertiary care sample
(n = 100) and pain-free patients with depression or post-traumatic stress disorder and pain-free healthy controls
(each n = 30, respectively). The samples will be pain localisation matched by sex and age to the population-based
sample. Patients will undergo physical examination and thorough assessments of mental co-morbidity (including
psychological trauma), perceptual and central sensitisation (quantitative sensory testing), descending inhibition
(conditioned pain modulation, the diffuse noxious inhibitory control-like effect), as well as measurement of the
plasma levels of nerve growth factor and endocannabinoids.
Discussion: The identification of the underlying pathophysiologic mechanisms in different subgroups of chronic
musculoskeletal pain patients will contribute to a mechanism-based subgroup classification. This will foster the
development of mechanism-based treatments and holds promise to treat patients more sufficient.
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Background
Chronic pain conditions of the musculoskeletal system
are common and of high socioeconomic relevance [1-4].
This is especially true for pain conditions with widely
unknown pathogeneses, such as non-specific chronic
back pain (CBP), chronic widespread pain (CWP), and
fibromyalgia syndrome (FMS). In addition, the preva-
lence of these conditions and the demand for consult-
ation and treatment have increased over recent years
[5,6], which results in high direct and indirect costs
[1,3,7,8].
However, therapeutic approaches in chronic musculo-
skeletal pain patients are often of minor success [9-16].
This is likely because the aetiology and pathogenesis of
chronic musculoskeletal pain are still widely unknown. As
a result, treatment for this condition involves predomin-
antly unspecific interventions, although the group of
chronic musculoskeletal pain patients is believed to be
heterogeneous [17,18]. Differences in response to the
same treatment in patients with the same disease could
be explained by different underlying mechanisms con-
tributing to the generation and maintenance of pain
[19,20]. The situation is complicated by the finding that
the same disease can derive from various pathophysio-
logical mechanisms. Conversely, the same pathophysio-
logical mechanism may be of interest in distinct diseases
[20].
The heterogeneity is supported by strong hints that
subgroups exist that differ in terms of aetiopathology,
clinical symptomatology, and psychophysiological pat-
terns. A recent study revealed distinct somatosensory
profiles in CBP and FMS: FMS patients showed
increased sensitivity for different pain modalities in all
measured body areas, which suggests central disinhib-
ition (or a deficient pain inhibitory system) as a potential
mechanism. CBP subjects, in contrast, exhibited loca-
lised alterations within the affected segment. Such
alterations may be due to peripheral sensitisation [21].
This finding is in accordance with the main hypothesis
of a mechanism-based diagnosis in chronic pain syn-
dromes, which proposes that defined symptoms and
signs reflect possible underlying neurobiological pain
mechanisms [19,22]. Consequently, these subgroups
should be treated with specific mechanism-based
approaches, but to date, they have been treated with the
same non-specific multimodal treatment programs.
Therefore, the assessment of chronic pain and research
identifying various factors associated with the develop-
ment, maintenance, and spread of chronic pain, includ-
ing their neurobiological correlates, is highly relevant.
Chronic pain has been found to be associated with a
higher prevalence of mental co-morbidity. Patients with
CBP [23,24], CWP [25], and FMS [26] suffer from men-
tal disorders significantly more often than pain-free
controls. This finding is especially true for anxiety disor-
ders and mood disorders, which were found to have
prevalence rates of 20.9% and 12.7%, respectively, in a
population-based sample of patients with chronic back
pain [23]. Of further interest is the role of psychological
trauma, which has been neglected in previous research.
Traumatic events have higher prevalence rates in patients
with pain compared to pain-free controls or patients with
other diseases [27-29]. Concerning traumatic experiences,
it was suggested that multiple traumas have a cumulative
effect on physical health, including back pain and that
the impact of the trauma on health may be independent
of post-traumatic stress disorder (PTSD) symptomatol-
ogy [30,31].
The assessment of chronic pain and mental comorbid-
ity on a psychobiological basis may detect common
underlying pathophysiological changes. With regard to
pain processing there are studies that suggest a role for
central disinhibition mechanisms in depression and, to a
lower extent, in patients with FMS compared to healthy
controls [32]. Alterations in pain processing among
patients with depression or FMS were reported previ-
ously, but this study found that hyperalgesia was more
pronounced in patients with FMS than in those with de-
pression [33]. In patients with FMS with comorbid de-
pression or anxiety, pain processing was not altered in
comparison to patients with FMS alone [34]. Thus there
seems to be an association of chronic pain or depression
with altered pain processing, although chronic pain and
comorbid depression did not interact with pain
processing.
In regard to anxiety disorders and the neglected role
of trauma, a study by Defrin et al. described a unique
sensory profile of hyposensitivity to non-noxious stimuli,
accompanied by hypoalgesia to at-pain-threshold nox-
ious stimuli and hyper-reactivity to suprathreshold nox-
ious stimuli in patients with PTSD and chronic pain
compared with healthy controls [35].
This pattern clearly differs from other patient groups
with chronic pain, such as those with fibromyalgia, who
tend to exhibit pain hypersensitivity [21,36], and from
alterations in PTSD, in which context a decreased sensi-
tivity to painful stimuli has been reported [37,38]. The
results reported by Defrin et al. appear to be a hybrid of
what has been found in pain-free PTSD patients and
PTSD-free pain patients: decreased sensitivity to non-
painful stimuli and increased hyperreactivity to painful
stimuli. Sensory processing in anxiety disorders other
than PTSD is believed not to differ from processing in
healthy controls [35]. Another aspect of the psychobiol-
ogy of pain is pain inhibition. It was found that pain in-
hibition is deficient in FMS patients but normal in those
with depressive disorder [33]. Another study reports evi-
dence that pain inhibition in FMS is more pronounced in
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patients with comorbid depressive symptoms compared
to those with FMS alone [39]. However, due to hetero-
genic sample selection and different testing methods, the
results in regard to pain processing and pain inhibition
in chronic pain and mental disorders are inconsistent
and partially contradictory [40]. Therefore, a compre-
hensive measurement of the clinical manifestation and
psychobiological aspects of chronic pain is necessary.
To challenge the topic of a mechanism-based sub-
group classification of chronic pain patients and to es-
tablish specific mechanism-based treatments [41],
further variables of interest must be considered to guar-
antee a more holistic approach, compared to that pur-
sued in prior research. Therefore, we developed a
theoretical framework (Figure 1), which investigates the
role of chemical sensitisation (nerve growth factor;
NGF) [42-46], the endocannabinoid system [47,48], and
other psychological variables (e.g. early stress exposure,
stress and pain coping, resilience) [49-51] as well as gen-
etic variables [52-54] in addition to mental comorbidity
and psychophysiological patterns. NGF is an important
key mediator of some forms of persistent pain and plays
an important role in the switch from acute to chronic pain
as well as the spatial spread of pain [42-46]. The endocan-
nabinoid system refers to a group of neuromodulatory
lipids that is relevant for pain memory and pain extinc-
tion [47,48]. Accordingly, these variables have proven to
be of interest in chronic pain and to be promising in
its treatment. In line with that, the current study
addresses the association between the clinical manifest-
ation of chronic musculoskeletal pain (including mental
comorbidity) and neurobiological changes.
Therefore, the purpose of the present study is to 1)
identify and describe subgroups of patients with muscu-
loskeletal pain with regard to clinical manifestation (in-
cluding mental comorbidity), 2) investigate whether
distinct sensory profiles due to different underlying
mechanisms can be distinguished in different subgroups
of pain patients 3) and to measure plasma nerve growth
factor levels and to analyse distinct endocannabinoid
profiles in different subgroups of pain patients.
Methods
This study is part of the consortium ‘Localized and Gen-
eralized Musculoskeletal Pain: Psychobiological Mechan-
isms and Implications for Treatment (LOGIN)’ funded
by the German Federal Ministry of Research and Educa-
tion (01EC1010A-F). More details concerning LOGIN
can be found elsewhere [55,56]. This report focuses on
subproject number six (SP6) ‘Subgroups Characterised
by Psychological Trauma, Mental Co-morbidity, and
Psychobiological Patterns and Their Specialised Treat-
ment’. All participants must provide written informed
consent before inclusion in the study. The study has
been approved by the Ethics Research Committee of the
Faculty of Medicine, University of Heidelberg (S-261/
2010) and will be carried out in compliance with the
Helsinki Declaration.
Design
The study uses a descriptive and exploratory design. We
will include 200 patients with chronic musculoskeletal
pain from different settings (a population-based setting
and a tertiary care setting) and 90 controls (pain-free
patients with PTSD, depression, and healthy controls
without mental disorders). All participants will undergo
a physical examination. The relevant sociodemographics
and measures of clinical manifestations of chronic pain
are reported in Table 1: measurements of potential
pathophysiological mechanisms are reported in Table 2.
Samples and patient recruitment
We will recruit patients with non-specific chronic mus-
culoskeletal pain as well as control subjects that are
not in pain: 1) Population-based sample: In a previous
population-based study (“Generalization of Pain: A
prospective population-based survey with clinical
examination” as part of the German Back Pain Re-
search Network, supported by the Federal Ministry of
Education and Research; [21,23,57,58]), we established
a representative sample of patients with chronic local
and chronic widespread back-pain. For the present
study, 100 patients from this representative study sam-
ple will be randomly recruited. 2) Tertiary care setting:
We will recruit 100 consecutive musculoskeletal pain
patients from the tertiary care Musculoskeletal Pain
Centre at the University Hospital Heidelberg. 3) Con-
trol subjects: To determine whether the results are
specific for pain, we will further investigate three
groups of pain-free patients: a) PTSD patients (n = 30),
b) patients with depression (n = 30), and c) healthy con-
trols (n = 30). Patients with PTSD and depression will
Figure 1 Theoretical framework of our project.
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be recruited in our Psychosomatic Outpatient Centre
at the University Hospital of Heidelberg. Healthy con-
trols will be recruited by flyers posted around the local
community. All groups will be matched with respect
to age, sex, and (if appropriate) pain location to our
population-based sample. Thus, we will include at least
200 patients with non-specific chronic pain and 90
pain-free subjects.
Inclusion and exclusion criteria
The inclusion criteria for pain samples are non-specific
chronic musculoskeletal pain lasting for ≥ 45 days during
the past three months, at least 18 years of age, and flu-
ent German language skills. All control participants
(participants with PTSD, depression, and healthy con-
trols) should be pain-free. Because the point prevalence
of back pain in the German population was more than
one third and the 1-year prevalence was higher than 75%
[57], the recruitment of patients that were absolutely
pain free within the last three months, will not be feasible
and will not reflect reality. Therefore, we aim to recruit
only absolutely pain-free participants. If this is not pos-
sible, we will define pain-free as follows: 1) less than one
day (< 24 hours) spent in pain per week within the last
three months. 2) Pain intensity < 3 on an 11-point nu-
meric rating scale on the days when the patient is in pain.
3) Pain does not interfere with normal activities or work.
These criteria are adapted from standardised definitions
Table 1 Variables and methods used to assess clinical manifestations of chronic non-specific musculoskeletal pain
Questionnaires Variables
Chronic Pain Grade Questionnaire (CPG)* [65,66] Severity of chronic pain problems (disability, pain intensity)
Pain Experience Scale (SES) [64] Sensory and affective descriptors of pain
12-Item Short-Form Health Survey (SF-12)* [74,75] Health-related quality of life
Resilience Scale (RS11)* [97,98] Resilience (personal competence, acceptance of self and life)
Hospital Anxiety and Depression Scale (HADS-D)* [99,100] Anxiety and depression
Childhood Trauma Questionnaire (CTQ)* [72,73,101] Childhood and adolescence maltreatment (physical and emotional abuse,
sexual abuse, physical and emotional neglect)
Pain drawing (pain location) [62] [63] [6] Perceived location(s) of pain will be assessed using digitised pain drawings.
Classification into categories of chronic local and chronic widespread pain.
Sociodemographics (self-report questions) Age, sex, marital status, education, employment status
Interviews
Structured Clinical Interview for DSM-IV Axis I
Disorders + Axis II (SCID I + II)* [69]
DSM-IV Axis-I and Axis-II mental disorders
Physical examination
ACR Criteria for Fibromyalgia (ACR Classification)
[62] [102]
Tenderpoint count and documentation of specific symptoms
Physical Impairment Scale (PIS) [67] Physical impairment (total flexion, total extension, average lateral flexion,
straight leg raising, spinal tenderness, bilateral active straight leg raising, and sit-up)
Back Performance Scale (BPS) [68] Disability. Tests of daily activities (Sock Test, Pick-up Test, Roll-up Test,
Fingertip-to-Floor Test, and Lift Test)
* German Version.
Table 2 Methods used to assess the potential mechanisms involved in chronic non-specific musculoskeletal pain
Measures Variables
Quantitative Sensory Testing (QST) [76,103] Comprehensive profiles of somatosensory functions (thermal and mechanical detection
and pain thresholds, vibration thresholds, and pain sensitivity to sharp and blunt
mechanical stimuli). Discrimination between local vs. generalised and peripheral
vs. central nervous mechanisms.
Conditioned Pain Modulation (CPM, the diffuse
noxious inhibitory control-like effect) [77,78]
A descending pain inhibitory mechanism that inhibits nociceptive activity arising from
the afferent primary fibres at multiple levels of the dorsal horn, resulting in diffuse pain
inhibition. These descending pain pathways originate from the brainstem and have
significant inhibitory actions on nociceptive activity, thereby affecting pain perception.
Blood Tests
Nerve Growth Factor (NGF) Plasma NGF levels (proximity ligand ELISA techniques)
Endocannabinoids + related lipids (ECs) EC (anandamide (AEA), 2-arachidonoyl glycerol (2-AG), 1-arachidonoly glycerol (1-AG),
palmitoyl ethanol amine (PEA), oleoyl ethanol amine (OEA), arachidonic acid) in human
plasma (large- scale lipidomic profiling using the LC-MS/MS QTrap ABI5500)
Genetics 2* 9 ml EDTA tubes, stored for the second funding period
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of back pain [59] and its recurrence [60]. Participants
must also be pain free on the day of participation in the
study. Patients who have a previous history of chronic
pain will be excluded. Participants with PTSD and de-
pression must fulfill DSM-IV diagnoses of the respective
mental disorder. Patients with PTSD must be free of
affective disorders, and patients with depression must be
free of anxiety disorders. Healthy controls are not
allowed to meet any DSM-IV diagnosis. The exclusion
criteria are specific pathologies of CBP (e.g., spinal canal
stenosis, disc hernia, spondylolisthesis, infection, malig-
nancy, rheumatic and systematic inflammatory disorders,
and fracture), sciatica pain ≥ than back pain, diseases
affecting sensory processing (diabetes, alcohol or sub-
stance abuse, neuropathy, inflammatory diseases), pain
or surgery at the dorsum of the hand or back surgery in
the past three years (because the hand und back are to be
subjected to investigation), and cognitive impairment.
Procedure
Chronicity of pain
The number of painful days in the last three months
will be determined by a questionnaire and discussed
with a physician to rule out misunderstandings. To be
classified as suffering from chronic pain, the subject
must report experiencing back pain on ≥ 45 days in the
last three months.
Clinical examination
To verify the inclusion and exclusion criteria, all partici-
pants will be questioned about their past medical history
and about co-morbidities (neuropathy, diabetes, relevant
alcohol consumption, infections, inflammatory diseases,
disc hernia, previous severe injuries). Patients will also
receive a physical examination (general, rheumatological,
orthopaedic, and neurological), including blood tests
(and if indicated further technical investigations such as
x-ray or MRI) with special attention paid to findings that
indicate a specific origin of back pain. Therefore, the
“red flags” (hints of the presence of serious pathology
according to the Agency for Health Care Policy and Re-
search Low Back Guidelines) and yellow flags will be
considered [61], and former medical reports and dis-
charge letters will be taken into account whenever avail-
able. In the case of signs of serious pathological findings,
participants will be excluded, and a further investigation
will be advised. Painful tender points will be identified
by tenderness examination using ACR criteria [62].
Measures of clinical manifestation
The clinical manifestations of pain will be considered
using the pain dimensions (pain intensity, pain location/
extent, pain quality, and pain affect), disability/ impair-
ment (subjective as well as objective measures), and
psychological measures (mental comorbidity, early life
stress, health-related quality of life, and resilience).
Patients will be clustered in homogeneous groups
according to their clinical manifestation. In subsequent
analyses, we will test whether the clinical manifestation
corresponds with specific mechanisms (see below).
Pain dimensions
There are at least four dimensions of pain experience
that can be distinguished. These are intensity, location,
quality, and affect. Pain intensity: Pain intensity is
defined as how much a person hurts. It will be mea-
sured using a numerical rating scale, ranging from 0
‘no pain’ to 10 ‘worst pain imaginable’. Pain location:
Pain location can be defined as the perceived location
(s) of pain sensations that patients have on or in their
body. Spatial distribution patterns (local vs. referred
pain) will be assessed using a digitised pain drawings
[63]. Moreover, categorisation as CLP, CWP, and FMS
will be based on the ACR criteria [62] and a more
precise definition elaborated by Harkness et al. [6].
Therefore, each participant will be asked to complete a
body pain diagram, marking all areas where pain is
experienced. Afterwards, the pain diagram will be dis-
cussed jointly by the participant and the physician to
rule out any misunderstandings. Pain quality and pain
affect: Pain quality refers to the specific physical sensa-
tions associated with pain. Pain affect is the degree of
emotional arousal caused by the sensory experience of
pain. The affective and sensory dimensions of pain will
be measured using the Pain Experience Scale (SES).
The SES is the standard instrument of the German
chapter of the International Association for the Study
of Pain. The SES consists of 10 items on a sensory
subscale (e.g., ‘throbbing’, ‘wrenching’ or ‘stinging’) and
14 items on an affective subscale (e.g., ‘exhausting’,
‘fearful’, or ‘unbearable’). The response format is a
four-stage format (0 ‘not appropriate’; 1 ‘somewhat ap-
propriate’; 2 ‘generally appropriate’; 3 ‘fully appropri-
ate’). The sensory score of the SES is the mean of all
sensory items; the affective score of the SES is the
mean of all affective items. The retest-reliability of the
SES lies between .89 and .96, and Cronbach’s Alpha
lies between .72 and .92 [64].
Disability/ impairment
Chronic pain grade (CPG) The CPG assesses the sever-
ity of chronic pain problems. It measures pain intensity
and disability in regard to work and daily activities via
patients’ self-reports. The CPG comprises 6 items that
can be answered on an 11-point numerical rating scale
ranging from ‘0’ to ‘10’. The number of days during
which the patient experienced a disability during the
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past three months is assessed. Pain severity can be
graded in four hierarchical classes (Grade I, low disabil-
ity – low intensity; Grade II, low disability – high inten-
sity; Grade III, high disability – moderately limiting;
Grade IV, high disability – severely limiting). The CPG
has proven reliability (α= .82) and validity [65,66]. To
objectify impairment and disability, we will use the Phys-
ical Impairment Scale and the Back Performance Scale.
Physical impairment scale (PIS) The PIS was devel-
oped as a simple and standardised clinical observation
to evaluate physical impairment in patients with chronic
low back pain. The test battery combines objective phys-
ical findings indicating current functional limitations
due to pain. It consists of seven tests measuring lower
back movement (total flexion, total extension and aver-
age lateral flexion as measured with the inclinometer),
straight leg raises, spinal tenderness and strength (bilat-
eral active straight leg raises, sit-ups). The measurements
are translated into values of 0 or 1 according to cut-off
values and summed. As subjective disability in non-
specific low back pain is not explained by anatomic or
structural impairment, the PIS measures functional limi-
tation as influenced by the patient’s pain behaviour. The
PIS is able to discriminate between pain patients and
healthy controls and is related to self-reported disability
in the activities of daily living [67].
Back performance scale (BPS) The BPS is an objective
clinical assessment tool that can be used to observe
self-reported activity limitations in daily functioning
caused by lower back pain. The BPS consists of five
tests of daily activities (Sock Test, Pick-up Test, Roll-up
Test, Fingertip-to-Floor Test, and Lift Test) frequently
reported to be limited in back pain patients. Each per-
formance is evaluated by the observer according to op-
erational score definitions and then summed. The five
tests are combined to obtain a performance measure of
mobility-related activities requiring sagittal-plane mobil-
ity. The BPS is able to discriminate between pain
patients with different return-to-work statuses and is
sensitive to change. Cronbach’s α was .73 [68].
Psychological measures
Structured clinical interview for DSM-IV (SCID) To
examine the prevalence and the type of mental co-mor-
bidity, the SCID interview, which consists of two parts,
will be applied [69]. The SCID is a comprehensive and
highly reliable and valid instrument [70]. The SCID-I is
a semi-structured interview for the evaluation of major
DSM-IV Axis-I diagnoses. With the SCID-I, it is pos-
sible to derive both a current and a previous history of
psychiatric illness. The SCID-II procedure for assessing
personality disorders (PD) is a two-stage process. First,
subjects complete a 120-item questionnaire with ques-
tions based on the criteria from the DSM-IV. In the
second stage, a semi-structured interview is adminis-
tered. Positive answers must be re-evaluated by the
interviewer to diagnose Axis-II PD. According to the
SCID-II protocol, we will interview only those subjects
who achieve the cut-off (a specified number of positive
answers in a specific PD section) on the questionnaire
[69]. All SKID interviews will be conducted by two psy-
chologists with graduate training in clinical psychology.
To ensure diagnostic reliability, all interviews will be
audiotaped. One-fifth of the interviews will be randomly
selected and rated by both psychologists. A kappa coef-
ficient will be calculated to assess inter-rater reliability.
Both psychologists will conduct 10 SKID interviews in
a pilot phase. In cases of low inter-rater agreement fur-
ther, training will be conducted by an experienced
psychiatrist.
The Hospital Anxiety and Depression Scale (HADS-D)
will be used to determine the severity of anxiety and de-
pression. The HADS-D was especially developed for
patients with somatic diseases and thus excludes phys-
ical symptoms. Each scale consists of seven items that
measure anxiety and depression via the patient’s self-
report with a four-stage response format. The HADS-D
has good reliability (subscale depression: α= .81; subscale
anxiety: α= .80) and validity [71].
Childhood Trauma Questionnaire (CTQ The German
Version of the CTQ will be used to measure early stress
exposure. The CTQ measures maltreatment during
childhood and adolescence and will be applied because
it captures factors that are relevant to chronic pain [50]
that are neglected by the SKID. The CTQ consists of
five subscales (‘emotional abuse’, ‘physical abuse’, ‘sexual
abuse’, ‘emotional neglect’, and ‘physical neglect’). Cron-
bach’s α ranges from .89 to .96, except for the subscale
‘physical neglect’ which yields an α of .62 [72,73].
12-Item short form health survey (SF-12) The health-
related quality of life (HRQoL) will be measured with
the SF-12. The SF-12 consists of 12 items on eight scales
(‘physical functioning’, ‘role limitations due to physical
problems’, ‘bodily pain’, ‘general health’, ‘vitality’, ‘social
functioning’, ‘role limitations due to emotional problems’,
and ‘perceived mental health’). Response categories vary
from 2 to 6 and can be transformed to scale scores ran-
ging from 0 (‘the worst’) to 100 (‘the best’) [74,75].
Resilience scale (RS-11) Resilience is a personality
characteristic that moderates the negative effects of
stress and promotes adaption. Thus it avoids any poten-
tially negative effects of stress. Resilience will be
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measured with the RS-11. The RS-11 comprises two fac-
tors – ‘acceptance of self and life’ and ‘personal compe-
tence’ – with a seven-point response format ranging
from 1 ‘disagree’ to 7 ‘agree’. Thus, scores can range
from seven to 77, with higher scores reflecting higher re-
silience. The RS-11 has very good reliability (α= .91).
Sociodemographic variables
Sex, age, education, employment status, marital status
and further sociodemographic variables will by captured
by a questionnaire.
Measures of chronic pain mechanisms
We will determine whether the patient’s clinical manifes-
tations of pain correspond with various specific potential
pain mechanisms. In our study, potential mechanisms are
captured through quantitative sensory testing (QST), the
evaluation of conditioned pain modulation (CPM, the dif-
fuse noxious inhibitory control-like effect), and analyses of
nerve growth factor (NGF) plasma levels and endocanna-
binoid (ECs) profiles. Such potential mechanisms include
peripheral sensitisation, central sensitisation, disinhibition,
allodynia, and endogenous descending pain modulation.
Psychophysiological mechanisms
Quantitative Sensory Testing (QST) Somatosensory
function will be assessed using the comprehensive QST
protocol developed as part of the German Research Net-
work on Neuropathic Pain (DFNS). Seven tests measuring
13 parameters (warm detection threshold, cold detection
threshold, thermal sensory limen, paradoxical heat sensa-
tion, cold pain threshold, heat pain threshold, mechanical
detection threshold, mechanical pain threshold, mechan-
ical pain sensitivity, dynamic mechanical allodynia, wind-
up ratio, vibration detection threshold, and pressure pain
threshold) [76] will be conducted. QST testing covers all
relevant aspects of the somatosensory system including
large and small fibre function as well as signs of central
sensitisation (dynamic tactile allodynia, punctate mechan-
ical hyperalgesia). This way, detailed profiles of somato-
sensory function will be obtained for the tested body
areas. The test sites will be distributed throughout the
paraspinal muscles (5 cm±0.5 cm next to the midline on
the autochthon back muscles [L1 to S1]) and on the
dorsum of the ipsilateral hand.
Conditioned pain modulation (CPM) Inhibitory pain-
modulating mechanisms will be assessed using the CPM,
a diffuse noxious inhibitory control-like effect [77-79].
The difference in pressure pain threshold (PPT) before
and after the induction of DNIC by phasic heat pain
(PHP) will be measured. The appropriate temperature
for PHP will be determined by measurement of the heat
pain threshold (HPT). The PHP will oscillate ± 1°C
around the PHP-temperature. The ratings of PHP pain
intensity will be assessed using a computerised Visual
Analogue Scale (VAS). The HPT will be obtained using
ramped stimuli (1°C/s, 32°C baseline, 0°C and 50°C cut-
offs, 8 cm2 thermode), which will be terminated when
participants press a button. The mean of three consecu-
tive measurements will be calculated. The PPT will be
calculated as the mean of three consecutive measure-
ments over the paraspinal muscles (5 cm± 0.5 cm next
to the midline on the autochthon back muscles [L1 to
S1]; site contralateral to the QST).
Neurobiological measures
Nerve growth factor (NGF) NGF levels in human blood
samples will be determined using proximity ligand Elisa
techniques. Endocannabinoids (ECs): EC (anandamide
(AEA), 2-arachidonoyl glycerol (2-AG), 1-arachidonoly
glycerol (1-AG), palmitoyl ethanol amine (PEA), oleoyl
ethanol amine (OEA), arachidonic acid) analyses of human
blood samples will be performed by large-scale lipidomic
profiling using the LC-MS/MS QTrap ABI5500. All ana-
lyses of NGF and ECs will be performed in collaboration
with our consortium partners.
Sample size estimation
A sample of more than 200 musculoskeletal pain
patients (population-based sample and tertiary care
sample) will be acceptable in order to recruit a suffi-
cient number of “cases” with different clinical manifes-
tations (e.g., local vs. generalised pain, different levels
of pain affect, anxiety disorders, mood disorders, no
mental comorbidity). To estimate the number of
patients in different subgroups, we will refer to data
from our population-based study. Approximately 61.8%
of the patients in our population-based study had
chronic local pain (CLP), and 38.2% had chronic wide-
spread pain (CWP). We also found a prevalence of
12.7% for depression and 20.9% for anxiety disorders
(using the SCID-I). The prevalence of depression and
anxiety may be higher in a tertiary care pain setting,
as reported by others [80,81]. Therefore, we expect
group sizes that will be sufficient to gather abundant
information regarding clinical manifestations. We also
consulted recent QST studies and a review regarding
DNIC to estimate the required group sizes. For DNIC
testing, a systematic review [82] evaluated studies with
an average group size of 20. A group size of 20 to 30
is also commonly used in recent QST studies
[21,63,83]. We therefore expect our group sizes to be
appropriate for the investigation of distinct sensory
profiles. Studies investigating endocannabinoids used
sample sizes between n = 10 and n = 20 patients per
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group and reported mean effect sizes between .60 and
.80 (e.g. [84,85]). Studies with NGF have reported ef-
fect sizes between 2.02 and 4.31 [44,86]. With regard
to pain mechanisms, small sample sizes are sufficient
to compare subgroups. This will also apply for the
groups of pain-free patients with PTSD, depression,
and healthy controls (each n= 30, respectively).
Quality assurance
To ensure that the measurements are reliable and high
in quality, the project will have a pilot phase. In this
pilot phase the study staff will be trained in the study
procedures (if necessary) and conduct paired measure-
ments to ensure reliability and validity. The pilot phase
will be finished when the reliability and validity of the
measurements has been verified. The study protocols
will be tested and adapted if necessary.
Statistical analyses
Descriptive statistics will be presented with means and
standard deviations for continuous variables and abso-
lute numbers and percentages for categorical variables.
Questionnaires will be dealt with according to question-
naire manuals. The prevalence of chronic local pain,
chronic widespread pain, fibromyalgia, and mental
comorbidities will be determined for the population-
based sample and tertiary care setting. Explorative clus-
ter analysis will be conducted to establish subgroups
based on the clinical manifestations observed. Therefore,
the dimensions of pain (see above) and mental comor-
bidity will be used as cluster variables. Then, we will
explore whether different neurobiological profiles (QST
profiles, CPM, NGF levels, EC profiles) correspond
with these subgroups. Pain drawings will be scanned,
superimposed, and transformed into two-dimensional
color-coded images. Body areas with high occurrence
of pain will be illustrated in dark red; body areas without
pain will appear in white. To classify patients who suffer
chronic local pain (CLP) or chronic widespread pain
(CWP), pain drawings will be analysed according to the
ACR criteria [62] and a more precise definition [6].
Quantitative sensory testing (QST) data pre-processing
and statistical analysis will be performed according to
the protocol established by Rolke et al. [76]. To quantify
conditioned pain modulation (CPM), the PPT before
PHP will be subtracted from the PPT after PHP. Nega-
tive values indicate an analgesic effect due to CPM. Dif-
ferences between patient groups will be analysed using
analyses of co-variance (ANCOVA), followed by Fisher’s
least significant difference test. Potential confounders
will be included as covariates, if indicated. QST modal-
ities or CPM will be entered as dependent variables, the
patient groups as an independent variable. For more
detailed information analysing QST data, we will refer to
the protocol proposed by Rolke et al. [76]. The same
procedure will be applied with regard to nerve growth
factor (NGF) and endocannabinoids (ECs).
Discussion
Establishment of a mechanism-based subgroup classifi-
cation of pain and the development of specific treat-
ments were suggested almost a decade ago [41]. Since
then, the topic has been discussed amid controversy
[19,22,87,88]. Small effect sizes of chronic pain treat-
ments were suspected to be due to unspecific treatment
approaches, but different pain generating and maintain-
ing mechanisms [19,20]. This possibly is also supported
by clinical experience, which shows that the subgroups
of chronic pain patients are heterogeneous, even if suf-
fering the same disease like non-specific chronic back
pain. However, only a few studies have aimed to identify
different pain mechanisms [20,21]. The identification of
patient subgroups is needed if we wish to establish dis-
tinct pathophysiological mechanisms and targets that are
necessary for the development of new analgesic drugs
and non-pharmacological mechanism-based treatment
options. There is a corresponding lack of evidence for
subgroup-specific treatments.
In addition to the identification of specific patho-
physiological mechanisms, we will implement a feasibil-
ity study that is designed as a randomised controlled
trial. We will adapt the proven Eye-Movement-
Desensitization-Reprocessing (EMDR) short-time ther-
apy to the subgroup of patients with chronic pain who
have experienced psychological trauma. This approach
might be promising because EMDR is an effective treat-
ment for patients with PTSD [89,90] or chronic pain
[91-94] but has not yet been adapted to patients with
chronic musculoskeletal pain who have experienced psy-
chological trauma. However, there are initial signs that
this might be a promising approach [95,96]. To identify
potential underlying mechanisms, we will use all mea-
surements of our study obtained before and after treat-
ment (plus functional magnetic resonance imaging).
Thus, our study will foster the development of new,
more specific interventions for chronic pain patients.
The remaining challenge is to match a sign or symp-
tom to a mechanism, but a sign or symptom could po-
tentially be produced by several distinct mechanisms
[19,20]. The novel aspect of our research is therefore its
comprehensive approach that uses reliable and valid
diagnostic tools. This approach comprises many vari-
ables that have been shown to be involved in alterations
in sensory processing (e.g., mental comorbidity, descend-
ing pain modulating systems, nerve growth factor, endo-
cannabinoids). A holistic approach is also needed
because research shows that these variables influence
each other [35]. The observed alterations might be
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hybrids of alterations caused by single variables [21,37].
The inclusion of a population-based sample is also rea-
sonable because prior research is usually based on highly
selective clinical samples of pain patients, and this might
bias research. Notably, the study is part of the LOGIN
consortium. LOGIN comprises seven subprojects and
includes basic and applied research in animals and
humans as well as preclinical and clinical projects. All
projects will use a core set of variables that investigates
similar pathogenetic mechanisms. This approach enables
LOGIN to study aspects in animals that cannot be inves-
tigated in humans (e.g., pathophysiological processes in
the spinal cord or brain) and to transfer results to the
human subprojects and vice versa. This approach will be
fostered by the translational aspects of LOGIN. Thus,
using the synergy of the different subprojects, the con-
temporary translation, implementation and dissemin-
ation of the results will be guaranteed.
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